ORIGINAL PAPER

Ligand specificity of odorant receptors

Kamil Khafizov • Claudio Anselmi • Anna Menini • Paolo Carloni

Received: 31 March 2006 / Accepted: 12 September 2006 / Published online: 21 November 2006 © Springer-Verlag 2006

Abstract Odorant receptors belong to class A of the G protein-coupled receptors (GPCRs) and detect a large number of structurally diverse odorant molecules. A recent structural bioinformatic analysis suggests that structural features are conserved across class A of GPCRs in spite of their low sequence identity. Based on this work, we have aligned the sequences of 29 ORs for which ligand binding data are available. Recent site-directed mutagenesis experiments on one such receptor (MOR174-9) provide information that helped to identify nine amino-acid residues involved in ligand binding. Our modeling provides a rationale for amino acids in equivalent positions in most of the odorant receptors considered and helps to identify other amino acids that could be important for ligand binding. Our findings are consistent with most of the previous models and allow predictions for site-directed

Electronic supplementary material Supplementary material is available in the online version of this article at http://dx.doi.org/ 10.1007/s00894-006-0160-9 and is accessible for authorized users.

K. Khafizov C. Anselmi A. Menini P. Carloni International School for Advanced Studies, via Beirut 4, I-34014 Trieste, Italy

K. Khafizov · C. Anselmi · P. Carloni (⊠) INFM-DEMOCRITOS Modelling Centre for Research in Atomistic Simulation, via Beirut 4, I-34014 Trieste, Italy e-mail: carloni@sissa.it

K. Khafizov · C. Anselmi · A. Menini · P. Carloni Italian Institute of Technology, via Beirut 4, I-34014 Trieste, Italy mutagenesis experiments, which could also validate our model.

Keywords Olfactory receptors · Sequence alignment · Odorant binding · G protein-coupled receptor · Homology modeling

Abbreviations

OR	odorant receptor
3D	three-dimensional
SI	sequence identity
GPCR	G protein-coupled receptor
TM	transmembrane

Introduction

The olfactory system detects and distinguishes among a large number of structurally diverse odorant molecules. In the nasal cavity of vertebrates, volatile molecules interact with odorant receptors (ORs), which are located in the cilia of olfactory sensory neurons. The odorant binding to ORs activates a transduction cascade that leads to the production of action potentials, which are transmitted to the brain (for review, see Menini et al. [1]).

Mammalian ORs were first identified in 1991 by Buck and Axel [2]. Because of the difficulty in expressing ORs on the membrane surface of heterologous cells, to date only a limited number of relations between ORs and odorant molecules could be provided (for reviews see Mombaerts [3] and Godfrey et al. [4]). One odorant can activate numerous types of ORs, while a single OR can be activated by several different odorants [5]. Each type of odorant molecule is recognized by the activation of a unique combination of ORs in a combinatorial code. ORs have been subdivided in two classes: [6, 7] Class #1 ORs, the socalled fish-like ORs, which share a rather high sequence identity (SI) and Class #2 ORs, mammalian-like ORs, which comprise all the others. Class #1 ORs bind structurally similar ligands [5, 8] such as aliphatic acids, alcohols, aldehydes and so on, whereas Class #2 ORs bind structurally divergent odorants [5, 8–19].

ORs belong to Class A of the GPCR superfamily, the so-called Rhodopsin-like Class [20]. They feature seven transmembrane (TM) helices in the membrane domain, an extracellular N-terminus and an intracellular C-terminus [20]. Resting on the significant divergence of SI and on the results obtained by site-directed mutagenesis experiments, helices TM3, TM4, TM5 and TM6 are believed to form the binding pocket [1, 14, 21]. Since there is still a lack of experimental structures at atomic level, structural information on ORs is essentially based on computational methods.

As for the prediction of the entire transmembrane domain, structural models of some ORs were based on the bacteriorhodopsin X-ray structure [22-24] or on a lowresolution (7.5 Å) electron-microscopy map of rhodopsin [21, 25-29]. Molecular-dynamics simulations of one of these models, the rat OR I7, [28] helped to identify the dissociative pathway along which the ligand accesses the pocket [30]. Models of ORs (MOR31-2, MOR32-4, MOR33-1, MOR42-1, MOR42-3, MOR103-15, MOR175-1 and MOR204-32) were also predicted using molecular-simulation based protocols [31-34]. These models were structurally rather different from each other and from rhodopsin, although several positions in TM3 and TM6, which are involved in ligand binding, are conserved across the family. The binding pockets of these models turned out to be constituted by helices TM3 to TM7 along with extracellular loops. Free-energy calculations based on these models turned out to be in agreement with experimentally-determined binding affinities [9–11, 15].

Man et al. [35] suggested that residues that might be involved in ligand binding in ORs are located on helices TM2 to TM7 and on the second extracellular loop. Their work was based on a comparison between mouse and human OR sequences, under the assumption that functional contact residues would be conserved among pairs of orthologous receptors, but considerably less conserved among paralogous pairs [35]. Recently, Katada et al. [14] published a study that combines computational biology with molecular biology tools. They performed several sitedirected mutagenesis experiments for MOR174-9 OR to identify residues involved in ligand binding and selectivity and recognized nine crucial amino acids—Ser113, Phe206, Asn207, Thr211, Leu212, Phe252, Thr255, Ile256 and Leu259—located on helices TM3, TM5 and TM6. Models based on the bovine rhodopsin X-ray structure, [36] which is the only GPCR for which an X-ray structure has been determined, were fully consistent with the experimental results [14].

The reliability of homology models for ORs has been questioned, based on first-principles simulations and the low SI between rhodopsin and ORs (in the case of those considered in this work it ranges between 14 and 20%) [31–34]. However, homology models with low SI (ranging from 10 to 30%), based on rhodopsin and other templates, have been reported for a variety of membrane proteins [37–39]. These models provided insights into structure/function relationships for these systems. In addition, the recent observation that structural features are well conserved across all class A GPCRs [40], which include ORs and rhodopsin, has led to the conclusion that OR rhodopsin-based structural predictions may be reliable, strengthening a posteriori the conclusions of Katada et al. [14].

Prompted by these studies, we have here extended the rhodopsin-based modeling to 29 ORs for which ligand affinity data have been measured (Table 1). Because of the aforementioned structural conservation, we postulate that: (1) the presence of conserved residues in ORs binding ligands possessing the same functional groups may provide hints on their functional role, in spite of the low SI across the family. This assumption is further substantiated a posteriori by an analysis of the sequences, which shows that, based on this assumption, ORs binding to specific ligands feature conserved residues that bind to those ligands. (2) The relative orientation of the seven TM helices is similar across the OR family, in spite of the diversity of their sequence [2, 5, 35].

In addition, the structural information for MOR174-9 [14] may be included in the modeling for most ORs (Table 1), given the structural conservation among members of GPCR family [40]. Our calculations permit us to identify a number of residues located on helices TM3, TM4, TM5 and TM6, which may play a role in odorant binding for 23 out of the 29 ORs considered (Fig. 1 and Table 1). For these receptors, mutations in the putative binding site were also suggested. These mutations could be used to validate the model against molecular biology experiments.

Materials and methods

Sequence alignments

The sequences of mouse ORs for which binding affinity data are available [5, 8, 10-18] (Fig. 2), were aligned using the ClustalW multiple alignment program [41].

Class of odorants	Total number of carbons in aliphatic chain (N)	ORs	Main residues in binding pocket					
c	9	MOR8-2 (S86)	3 (H), 4 (S), 5 (A), VI (F), VII (P), VIII (V), IX (L)					
	7–9	MOR22-2 (S41)	3 (H), 4 (Q), II (T), III (G), VII (P), 13 (F)					
	7–9	MOR23-1	3 (H), 4 (Q), II (A), III (I), VII (L), 13 (F)					
	5-6	MOR31-2 (S18)	3 (H), 4 (F), 5 (V), 9 (S), II (A), VI (F), VII (P), 13 (F)					
	6–10	MOR31-4	3 (H), 4 (F), 5 (I), 9 (S), II (L), VI (F), VII (P), 13 (F)					
	5	MOR31-6	3 (H), 4 (F), 5 (V), 9 (S), II (V), III (M), VI (F), VII (P), 13 (F)					
	9–10	MOR32-4 (S46)	3 (H), II (S), III (M), V (V), VII (P), 13 (F)					
	10	MOR32-5	3 (H), II (S), III (V), V (L), VII (P), 13 (F)					
	8-10	MOR32-11	3 (H), II (S), V (M), VII (P), 13 (F)					
	6–9	MOR33-1 (S19)	3 (H), 4 (F), 5 (A), 9 (T), III (V), VII (P), 13 (F)					
	7–9	MOR40-1 (S51)	3 (N), 4 (L), 5 (T), III (L), VII (V), 13 (V)					
	8–9	MOR40-4 (S83)	3 (H), 4 (V), 5 (A), III (L), VII (V), 13 (V)					
	7–9	MOR106-1 (S1)	5 (T), II (F), III (V), VIII (V), 13 (V), IX (M) or 3 (F), II (F),					
			III (V), VII (T), 13 (V), IX (M)					
	9	MOR203-1	1 (L), 2 (V), 9 (I), 10 (F), VI (F), VII (T), 13 (Y) or 2 (V), 4 (V),					
			5 (T), I (C), 10 (F), II (F), III (N), 12 (I), VIII (L)					
a	8–9	MOR22-2 (S41)	3 (H), II (A), III (I), VII (L), 13 (F)					
u	7–9	MOR33-1 (S19)	3 (H) or 9 (T), III (V), VII (P), 13 (F)					
	8–9	MOR40-1 (S51)	3 (N) or 5 (T), 4 (L), III (L), VII (V), 13 (V)					
	9	MOR40-4 (S83)	3 (H), 4 (V), 5 (A), III (L), VII (V), 13 (V)					
	5-7	MOR106-13P (S3)	3 (F), 5 (S), I (C), II (L), III (P), 13 (V), IX (M) or 3 (F), I (C),					
			II (L), III (P), 12 (L), VII (S), 13 (V), IX (M)					
	6–7	MOR204-32 (S25)	3 (V), 5 (T), III (I), VIII (I), 13 (F), IX (I) or 3 (V), III (I),					
			11 (L), VII (T), 13 (F) or I (S), III (I), V (V), VI (F), VIII (I)					
d	6–9	MOR13-6 (S85)	3 (H), 4 (S), III (A), VII (P), 13 (S), IX (V)					
	9	MOR42-1 (S50)	3 (Y), 4 (I), 5 (V), II (F), 12 (T) or VII (S) or 13 (S) or IX (S)					
	9	MOR42-3 (S6)	3 (Y), 4 (I), 5 (V), 9 (T), II (F), 12 (T) or VII (S) or 13 (S) or IX (S)					
e	5	MOR31-6	2 (V), II (V), III (M), VI (F), <i>VIII</i> (S), 14 (L)					
C	6–10	MOR103-15 [20]	2 (F), 3 (L), 5 (C), I (C), 9 (I), II (F), III (I), VI (F), VIII (S), IX (I)					
	7	MOR175-1 (OR912-93)	2 (F), 3 (S), 5 (V), II (I), III (L), VI (L), VIII (L), IX (I)					
g		MOR171-2 (M71)	2 (F), 3 (L), 4 (V), 5 (I), I (C), 9 (F), II (F), VI (F), VIII (T), IX (M)					
		MOR258-5	2 (F), 3 (L), 4 (G), 5 (I), 9 (I), II (I), III (L), VI (M), <i>VIII</i> (C), IX (M) or 2 (F), 3 (L), 4 (G), 5 (I), <i>I</i> (S), 9 (I), 10 (L), II (I), III (L), VI (M), IX (M)					

Table 1 Residues in the putative binding pocket of mouse ORs identified by this study

The class of odorants, the total number of carbon atoms in the ligand, the names of the receptors are here reported using the same labelling schemes of Fig. 2. Commonly used OR names are reported in parenthesis. Positions of residues likely to be involved in ligand–protein hydrogen bonds are in italics.

Three-dimensional structural models

Three-dimensional (3D) structural models of ORs (Fig. 1) were constructed using the MODELLER 6.2 program [42]. The calculations were based on the X-ray structure of bovine rhodopsin [43]. Sequences of ORs were aligned against the rhodopsin sequence using ClustalW [41]. The experimental information about residues that bind eugenol in the MOR174-9 receptor [14] was included into the alignment. To achieve this, (1) we considered the positions of the residues known to bind eugenol in the MOR174-9 receptor to be the more than the term of term of the term of the term of term of terms of the term of term of term of terms of the term of term of terms of the term of term of terms of the term of term of terms of terms of the term of terms of te

face the active-site cavity [14]. (2) We looked at the alignments of MOR174-9 with the other receptors and identified the corresponding positions of the latter proteins. These positions were assumed to belong to residues facing the active-site cavity. (3) The alignments of OR sequences against bovine rhodopsin sequence were modified manually according to this information. The alignments are available as supplementary material.

Energy minimization based on the parm99 AMBER force field [44] was carried out for all the 3D-models investigated here. The analysis presented in the Results and discussion section refers to such models.

Fig. 1 Side (a) and top (b) views of a representative structural model of ORs (C_{α} carbons in TM helices are only shown). The positions of the residues that may be involved in ligand binding are here indicated. Nine of them, indicated by *I* to *IX*, coincide with those previously obtained for MOR174-9 receptor [14]. Figures were created with VMD 1.8.2 program. [47]



Results and discussion

Comparisons among ORs

Here we attempt to provide a rationale for ligand binding to mouse ORs (Fig. 2) by first investigating the role of the nine residues, identified as constituents of the binding site in MOR174-9 (Ser113, Phe206, Asn207, Thr211, Leu212, Phe252, Thr255, Ile256 and Leu259) [14]. For purposes of clarity, we will refer to the positions occupied by these residues, as well as by the residues in equivalent positions in the other ORs, as positions I-IX throughout the text. We constructed approximate 3D-models for the 15 Class #1 ORs (Fig. 2) and the 13 Class #2 ORs (MOR103-15, MOR106-1, MOR106-13P, MOR171-2, MOR175-1, MOR203-1, MOR204-32, MOR258-5). However, for ORs MOR118-1, MOR136-6, MOR174-4, MOR267-13 and MOR276-1, the experimentally available information and/ or the similarity with other ORs is not sufficient to make reliable predictions for the binding pocket regions. Consequently, these ORs were not considered further.

We will first focus on Class #1 ORs, which share some common ligands, and later on Class #2 ORs, whose ligands are more variable.

Class #1 ORs

The odorant specificities of 15 Class #1 ORs have been tested experimentally [5, 8]. Aliphatic carboxylic acids were found to bind to 12 of the 15 Class #1 ORs, while dicarboxylic acids bind to the remaining three: MOR42-1, MOR42-3 and MOR13-6 (Table 1). We investigate here the role of residues in positions I-IX in the binding of aliphatic

carboxylic and dicarboxylic acids, in which the charged groups are at the ends of the chains, for the experimentally tested Class #1 ORs.

Position IV always has an Asp group. We suggest, at a speculative level, that this Asp could interact with a basic position in TM4 (indicated by a red arrow in Fig. 2) conserved across this class of ORs. Thereby, this position may serve structural and/or functional purposes, as previously noticed by Malnic et al. [5] Position I has polar residues in most ORs, with the exception of MOR42-1 and

Fig. 2 Sequences of all mouse ORs, for which ligand affinity data have been measured [5, 8, 10-18]. In the absence of a commonly agreed recent nomenclature for ORs, we have used the nomenclature proposed by Zhang and Firestein [7], in which Class #1 OR subfamilies are given numbers lower than 100 and Class #2 OR subfamilies are given numbers higher than 100. (For a comparison among different OR names see Table 5 by Godfrey et al. [4]). Only the sequences corresponding to helices TM3, TM4, TM5 and TM6 are here reported. Basic, acid, polar and Cys residues are colored in blue, red, green and yellow, respectively. Residues that have been shown to bind eugenol in MOR174-9 [14] are reported inside black boxes. Positions I to IX and I to 14, discussed in the text, are labelled. The position in TM4, mentioned in the text, is indicated with a red arrow above the alignment. Classes and specific ligands, which bind to corresponding ORs, are labelled on the right side. These are: a Alcohols, c carboxylic acids, b bromocarboxylic acids, d dicarboxylic acids, e alkylic aldehydes, f ketones, g benzaldehyde, h citronellal, i eugenol, *j* carvone, *k* acetophenone, *l* piperonal, *m* ethyl-vanillin, nvanillin, o citral, p limonene, q coumarin, r isovaleric acid, s cinnamaldehyde, t 2-octenal, u lyral, v chromanone, w 2-coumaranone [5, 8, 10-18]. Small differences in the response profiles of ORs to odorants have been found using different experimental systems by Malnic et al. [5] and Saito et al. [8] In case of discrepancy, we used the most recent experimental results obtained by Saito et al. [8] because their newly developed system of OR expression permits to perform site-directed mutagenesis experiments and to functionally test the odorant ligand specificity, whereas the pioneer studies by Malnic et al. [5] were obtained on isolated olfactory sensory neurons

ТМЗ			1	23	45	1				TN	14		•	67 8			
MOR8-2	SPN	CFA	FF	'I <mark>HE</mark> I	FSAM	SSVLL:	IM <mark>S</mark> F	RYIAI	128	SA	RVL <mark>Q</mark> I	GLAFS	L <mark>KN</mark> VI	CLIPELE.	V 163	C	
MOR13-6	AFD	A <mark>C</mark> LA	MFF	'I <mark>H</mark> FI	F <mark>SWT</mark>	SGILL?	AM <mark>S</mark> F	RYVAI	128	DA	RVAHM	GM <mark>S</mark> II	I RS F	MVFPLP	F 163	b, d	
MOR22-2	SFD	A <mark>CLL</mark>	2M <mark>2</mark> L	I H <mark>S</mark> I	FQAT	SGILLA	AMAL	RYVAI	128	PQ	L <mark>TT</mark> CL	GAGAL	L <mark>RS</mark> L]	TTFPLI	L 163	c, a, b	
MOR23-1	AFD	A <mark>CL</mark> T(LFF	'I <mark>H</mark> AI	L <mark>QG</mark> M	SGVLL2	AMAF	RYVAI	128	PL	FLL <mark>R</mark> V	VLVVA	IRAT	/LV <mark>G</mark> VLP	I 163	c	
MOR31-2	PFD	A <mark>C</mark> IA	OMFF	'I <mark>H</mark> V <i>F</i>	AFVA	SGILL?	AMAF	RYVAI	134	PM	AI <mark>G</mark> KM	TLAIW	GRSIC	TIFPII	F 169	c	
MOR31-4	SLD	R <mark>CIT(</mark>	2LFF	'I <mark>HS</mark> I	FI <mark>S</mark> E	SGILL ^V	/MAF	RYIAI	128	NS	LI <mark>G</mark> KI	GVGIF	L <mark>R</mark> SY(TIFPII.	F 163	C	
MOR31-6	AFD	A <mark>CVT</mark>	VFF	'V <mark>H</mark> TN	MFV <mark>G</mark>	SAILLA	AMAF	RFIAI	128	WS	TV <mark>G</mark> RI.	ALAIV	I <mark>RS</mark> I	CIIFPVI	F 163	c, r, e	
MOR32-4	AFR	DCVA	MFF	'I <mark>H</mark> LI	F <mark>TG</mark> I	TFMLVA	AMAF	RYIAI	128	NR	TICII	VGVGL	F <mark>KN</mark> F]	LVFPLI	F 163	c, b	
MOR32-5	AFG	A <mark>CIT</mark>	2M <mark>Y</mark> I	I <mark>HT(</mark>	C <mark>TG</mark> L	SVVLI	IAMI	RYIAI	128	NK	VIAIL	GIIII	V <mark>RT</mark> LI	LFV <mark>T</mark> PFI	F 163	c	
MOR32-11	SFG	GCLA	MFF	'I <mark>H</mark> VI	F <mark>TG</mark> M	TATTA I	7MA <mark>Y</mark>	RFVAI	128	NK	TISLL	L <mark>S</mark> VVI	G <mark>R</mark> NL]	LLV <mark>T</mark> PFV	F 163	c	
MOR33-1	SYH	G <mark>CL</mark> T(MFF	V <mark>H</mark> A'	VFAT	SAVLLA	AMAF	RYVAI	154	AV	VI <mark>G</mark> KI	GLA <mark>C</mark> V	TRGLI	FVFPFV	I 189	c, a, b	
MOR40-1	GFS	SCFL	OMFV	'M <mark>NS</mark> I	FL <mark>T</mark> M	SCIFV	CMAI	RYVAI	129		FVVRA	AIFVA	a <mark>rng</mark> i	IL <mark>T</mark> MPIP	I 162	c, a, b	
MOR40-4	SLP	CFA	<mark>omy</mark> a	IHCI	FVAM	SGIFV	CMAI	RYVAI	132	ES	FVV <mark>K</mark> A	TVIMA	I <mark>RN</mark> FV	APMSVP	V 167	c, a, b	
MOR42-1	SLP	R <mark>CLG(</mark>	OMFC	IYFI	LIVF	CNILLY	MAL	RYVAI	130	GQ:	LLACL	VVLAV	TRSTS	IVAPVV	V 165	d	
MOR42-3	SLP	R <mark>CLG</mark>	MFC	IYFI	LIVF	CNIFV	MAI	RYVAI	130	GQ	LLA <mark>C</mark> L	VVLAV	T <mark>R</mark> STS	IVAPVV	V 165	d	
MOR103-15	SF	ACMT(2LYF	FLGI	L <mark>GCT</mark>	CVLLAV	7MAY	RYVAI	131	SR	L <mark>CVQ</mark> M	AAGSW	AGGF	ISMVKV	F 166	e, o, h, s, t	
MOR106-1	SFS	GCFL	FYF	FF <mark>S</mark> I	GTT	CLFLA	7MA <mark>Y</mark>	RYLAI	136	RR	L <mark>CC</mark> IL	VSSCW	LICFI	GYPIPI	F 171	c, b	
MOR106-13P	SFS	GCFL	OFYF	FFSI	LGST	CFFLAV	/MAF	RYLAI	130	GR	L <mark>CN</mark> IL	VISCW	ILCFI	WFPVPI	I 165	а	
MOR118-1	SLL	GCFL	AFL	YFFI	GTT	FFLLA	7M <mark>S</mark> F	RYVAI	124	KR	VCVOL	VF <mark>CS</mark> W	MSGLI	LIIVP <mark>S</mark>	159	h	
MOR136-6	SHA	GCVS	TYF	FLLE	F <mark>GC</mark> I	NFLLT	MAY	RYVAI	126	os	LCVLL	VMVSW	AFSS	NGLVHT	L 161	i	
MOR171-2	SYV	GCMS	LYF	FLVE	FVIA	CYMLTY		RYVAI	126	PA	LCSLL	VAFVY	AVGLI	GSAT	160	k. a	
MOR174-4	SFV	CIV	OYFL	FCVE	FVV	AFLLV		REVAL	127	OK	LCITL	VVGSY	AWGE	CSLTLT	c 162	m. n	
MOR174-9	SFV	CLV	TTT	FCT	FVV	FLIG		REVAT	127	OR	LCAML	VLGSY	AWGVI	CSLTL.	162	i. m. n	
MOR175-1	SFT.	CAT	T.CT.	FSOR	FVV	CFLLA	MAY	RYVAT	126	OR	vevor.	VTGPY	STOFT	STMUHT	T 161	f.e	
MOR203-1	SFT	CT.A	L.L.V	VOTI	FVTS	CETLA	MAV	RVVAT	126	OR	LCTLL	LLCSY	TMOFT	NATVNT	161	c	
MOR204-32	PVA	CVA	LCT	VVAL	CTS	SFT.T.A	MAY	RVVAT	156	ST	VCTLL	VGTSY	LCCW	NAWTET	191	a	
MOR258-5	SYV	CVA	MYT	FT.MT	Стт	WT.FA	TMAN	RYVAT	129	PL	L.RGST.	VAFCC	FWGT	CALTYT	v 164	alavw	
MOR267-13	ST.A	CAT	MFF	FUT		CFLT.T.T.	MCY	RYVAT	126	KG	MCALL	VCCST	GTGL	MAVT.HV	P 160	ų, i, g, i, ii	
MOR276-1	SFA	COT	TCF	FUST	WCS	TTT	MAN	TAVVAT	95		VCLOT	ACCE	AFCTI	DO TTOM	130	n	
	N L LA		- -	TAN				TIT VIII	55	× F	A CTR T	in the second		The state of the s	v 100	P	
												1000					
TM5			10]]]]	V				тме			VI		K IA			
TM5	ENIT	TVOT	10 9				AT (TM6	TUCIO	TCAT	VI 12 V		(14 	266		
TM5 MOR8-2 MOR13-6	FNV	I <mark>YG</mark> LI	10 9 FVAL			// FIFM <mark>S</mark>	AL 2	221	TM6 RLKVLS	TCVS	II <mark>C</mark> AVI	VI 12 V	VIII IX II 13 PVISI	(14 AVI <mark>YR</mark> L2	A 266	c b d	
TM5 MOR8-2 MOR13-6 MOR22-2	F <mark>N</mark> V INS	9 I <mark>YG</mark> LI MYGLI	9 FVAL FIVI	III II SAFC		// FIFMS /LILLS	AL 2 VL 2	221	TM6 RLKVLS ERLKTLN		II <mark>C</mark> AVI	VI 12 V LIFYV	VIII IX II 13 PVISL PMISV	(14 AVI <mark>YR</mark> L# SMVHRF1	A 266 7 267	c b, d	
TM5 MOR8-2 MOR13-6 MOR22-2 MOR23-1	F <mark>N</mark> V INS INK	S I <mark>YG</mark> LI MYGLI I <mark>CG</mark> LI	10 FVAL FIVI LVAF	III TGI- SAFC AILC	V IV SVDSV SFDIV	// FIFMS) /LILLS /FI <mark>T</mark> FS)	AL 2 VL 2 V <mark>R</mark> 2	221 222 222 1	TM6 RLKVLS RLKTLN ARFKAFN	TCVSH TCVSH TCIAH	II <mark>C</mark> AVI IISAVI IICVFI	VI 12 V LIFYV LIFYV	VIII IX II 13 PVISI PMISV LAFFS	(14 SMVHRFV FFTHRF(FFTHRF(A 266 7 267 268	c b, d c, a, b	
TM5 MOR8-2 MOR13-6 MOR22-2 MOR23-1 MOR23-1	F <mark>N</mark> V INS INK INK	9 I <mark>YG</mark> LI MYGLI I <mark>CG</mark> LI SYGLI	10 FVAL FIVI LVAF	III TGI- SAFO AILO AILO	V IV -LDII SVDS SFDIV SFDIV	// FIFMS /LILLS /FITFS IFVFIS	AL 2 VL 2 V <mark>R</mark> 2 IL 2	221 222 222 222	TM6 BRLKVLS BRLKTLN ARFKAFN ARSKAFN	TCVSH TCVSH TCIAH	II <mark>C</mark> AVI IISAVI IICVFI IIVVFI	VI 12 V LIFYV LIFYV LQFYL LQFYL	VIII IX II I3 PVISL PMISV LAFFS	(AVI <mark>YR</mark> L SMVHRFV FF <mark>THRF(</mark> FF <mark>SHRF(</mark>	A 266 7 267 268 266 273	C b, d c, a, b c	
TM5 MOR8-2 MOR13-6 MOR22-2 MOR23-1 MOR31-2 MOR31-2	F <mark>N</mark> V INS INK INK VNI	YGLI MYGLI I <mark>CG</mark> LI SYGLI WYGFI	10 FVAL FIVI LVAF FVAF	III TGI- SAFC AILC AILC	V IV -LDII SVDS SFDIV SFDIV SFDIV	// FIFMS /LILLS /FITFS /FVFIS ALIGIS	YAL 2 YVL 2 YVR 2 YIL 2 YTL 2	221 222 222 222 222	TM6 BRLKVLS PRLKTLN ARFKAFN ARFKAFN ARHKALN	TCVSH TCVSH TCIAH TCTAH	II <mark>C</mark> AVI IISAVI IICVFI IIVVFI II <mark>G</mark> VII	VI IZV LIFYV LIFYV LOFYL LOFYL LEFI	VIII IX II I3 PVISI PMISV LAFFS LAFFS PSFFT	(AVI YRL SMVHRFV FFTHRF(FFSHRF(FLTHRF(A 266 7 267 268 266 273	C b, d c, a, b c	
TM5 MOR8-2 MOR13-6 MOR22-2 MOR23-1 MOR31-2 MOR31-4 MOR31-6	F <mark>N</mark> V INS INK VNI VNI	y I <mark>YG</mark> LI MYGLI I <mark>CG</mark> LI SYGLI WYGFI WYGFI	10 FVAL FIVI LVAF FVAF SVPM SVLI	III II SAFC AILC AILC ASVI	V IV SVDS SFDIN SFDMI LVDVF VLDVN	// FIFMS /LILLS /FITFS EFVFIS ALIGIS /LIFVS	AL 2 VVL 2 VVR 2 (IL 2 (TL 2 VVL 2	221 222 222 222 222 228 228	TM6 PRLKVLS PRLKTLN ARFKAFN ARFKAFN ARHKALN ARHKALN	TCVSH TCVSH TCIAF TCTAF TCGSH TCGSH	II <mark>C</mark> AVI II <mark>S</mark> AVI IIVVFI IIVVFI II <mark>G</mark> VII IVCIII	VI 12 V LIFYV LIFYV LQFYL LPFYI LLFFI	VIII IX II I3 PVISL PMISV LAFFS LAFFS PSFFT PGIFT	(AVI <mark>YR</mark> L# SMVHRFV FFTHRF(FFSHRF(FLTHRF(TLT <u>Q</u> RF(A 266 7 267 268 266 273 267 267	C b, d c, a, b c c c	
TM5 MOR8-2 MOR13-6 MOR22-2 MOR23-1 MOR31-2 MOR31-4 MOR31-6	F <mark>N</mark> V INS INK VNI VNI VNI	SYGLI MYGLI ICGLI SYGLI WYGF WYGF WYGF	10 FVAL FIVI LVAF FVAF SVPM SVLI SVPI	III TGI- SAFO AILO ASVI LTVV	V IV SVDS SFDI SFDI LVDVF VLDVF IVDVF	// FIFMS /LILLS /FITFS EFVFIS ALIGIS /LIFVS (LIAVS)	IAL 2 IVL 2 IVR 2 IL 2 IL 2 IVL 2 IVL 2 IVL 2	221 222 222 222 222 228 228 222 228	TM6 RLKVLS RLKTLN ARFKAFN ARFKAFN ARHKALN ARHKALN ARHKALN	TCVSH TCVSH TCIAH TCTAH TCGSH TCGSH TCGSH	IICAVI IISAVI IICVFI IIVVFI IISVIII IVCIII ILCVII	VI LIFYV LIFYV LOFYL LOFYL LLFFI LLFFI LLFFI	VIII IX II I3 PVISI PMISV LAFFS LAFFS PSFFT PGIFT PSFFT	(AVI YRL SMVHRFV FFTHRF(FFSHRF(FLTHRF(TLTQRF(LLTHRF(A 266 7 267 268 266 273 266 267 266	C b, d c, a, b c c c, r, e	
TM5 MOR8-2 MOR13-6 MOR22-2 MOR23-1 MOR31-2 MOR31-4 MOR31-6 MOR32-4	FNV INS INK VNI VNI VNI VNI	YGLI MYGLI ICGLI SYGLI WYGF WYGF WYGF LFGL	10 FVAL FIVI LVAF FVAF SVPM SVLI SVPI -ILI	III TGI- SAFC AILC AILC ASVI LTVV VMVI SMII	V IV STOR SFDIG SFDIG SFDIG SFDIG SFDIG SFDIG SFDIG SFDIG SFDIG SFDIG ST	// FIFMS /LILLS /FITFS /LIGIS /LIFVS /LIAVS /LIALS	ZAL 2 ZVR 2 ZIL 2 ZIL 2 ZIL 2 ZVL 2 ZAK 2 ZAK 2	221 222 222 222 222 222 228 222 222 222	TM6 RLKVLS RLKTLN ARFKAFN ARFKAFN ARHKALN ARHKALN ARHKALS ARLKALN	TCVSH TCVSH TCIAH TCTAH TCGSH TCGSH TCGSH TCGSH	IICAVI IISAVI IICVFI IIVVFI IICVIII ICCIII ICCIII ICCVII	VI IIFYV LIFYV LOFYL LFYI LFYI LFYI LFYI LAFFYV LAFFY	VIII IX II I3 PVISL PMISV LAFFS PSFFT PSFFT PSFFT PAFFS	(AVI YRL SMVHRFV FFTHRF(FFSHRF(FLTHRF(LLTHRF(FLTHRF(A 266 7 267 268 266 273 266 266 266	C b, d c, a, b c c c, r, e c, b	
TM5 MOR8-2 MOR13-6 MOR22-2 MOR23-1 MOR31-2 MOR31-4 MOR31-6 MOR32-4 MOR32-5	F <mark>N</mark> V INS INK VNI VNI VNI VNV VNV	YGLI MYGLI ICGLI SYGLI WYGF WYGF WYGF LFGL- IYGL-	10 FVAL FIVI FVAF FVAF SVPM SVLI SVPI -ILI -VAF	III II SAFO AILO AILO ASVI LTVV VMVI SMII SVG	V IV STDI STDI STDI STDI STDI STDI STDI STDI	// FIFMS /LILLS /FITFS FVFIS /LICIS /LIFVS /LIAUS /LIAUS /LIAUS /LIAUS	ZAL 2 ZVL 2 ZVR 2 ZIL 2 ZTL 2 ZVL 2 ZSL 2 ZAK 2 ZIR 2	221 222 222 222 222 222 222 222 222 222	TM6 PRLKVLS PRLKTLN ARFKAFN ARFKAFN ARHKALN ARHKALN ARHKALN ARLKALN ARLKALN	TCVS TCIA TCIA TCIA TCS TCS TCS TCS TCS TCS	IICAVI IISAVI IICVFI IICVII IICVII ICVII ICVII IVCVII IVCVII	VI IIFYV LIFYV LQFYL LQFYL LLFFI LLFFI LLFFI LAFFT LAFFT	VIII IX II I3 PVISI PMISV LAFFS LAFFS PSFFT PSFFT PAFFS PAFFS PALFS	(AVI YRL FFTHRF(FFSHRF(FLTHRF(LLTHRF(FLTHRF(FLTHRF(FMTHRF(A 266 7 267 268 266 273 266 266 266	C b, d c, a, b c c c, r, e c, b c	
TM5 MOR8-2 MOR13-6 MOR22-2 MOR23-1 MOR31-2 MOR31-4 MOR31-6 MOR32-4 MOR32-5 MOR32-11	FNV INS INK VNI VNI VNI VNV VNV INI	YGLI MYGLI ICGLI SYGLI WYGF WYGF LFGL- IYGL- IYGL-	10 FVAL FIVI EVAF SVPM SVLI SVPI -ILI -VAF -VVI	III TGI- SAF(AIL(AIL(AIL(SVI) SMII SVG) SFII	V IV SFDIG SFDIG SFDIG SFDMI LUDVE VLDVE LUDVE LUDVE LUDVE	// FIFMS /LILLS /FITFS IFVFIS /LIFVS /LIFVS /LIALS VIGFS ILIAS VIGFS	IAL 2 IVL 2 IVR 2 IL 2 ITL 2 IVL 2 IR 2 IR 2 IVL 2	221 222 222 222 222 222 222 222 222 222	TM6 PRLKVLS PRLKTLN ARFKAFN ARFKAFN ARHKALN ARHKALS ARLKALS ARLKALS	TCVS TCIA TCIA TCTA TCS TCS TCS TCS TCS TCS TCS	HCAVI HSAVI HCVFI HVVFI HCVII HCVII HVCVII HVCVII HVCVII HVCVII	VI IIFYV LIFYV LOFYL LOFYL LLFFI ILFYG LMFYV LAFFT LAFYL LAFYL	VIII IX II I3 PVISI PMISV LAFFS PSFFT PSFFT PAFFS PALFS PALFS	(AVI YRL FFTHRF(FFSHRF(FLTHRF(LLTHRF(FLTHRF(FMTHRF(FMTHRF(A 266 7 267 268 266 273 266 266 266 266	C b, d c, a, b c c c, r, e c, b c c	
TM5 MOR8-2 MOR13-6 MOR22-2 MOR23-1 MOR31-2 MOR31-4 MOR31-6 MOR32-4 MOR32-5 MOR32-11 MOR33-1	FNV INS INK VNI VNI VNI VNV VNV INI PNT	YGLI MYGLI ICGLI SYGLI WYGF WYGF LFGL- IYGL- IYGL- IYGL	10 FVAL FIVI EVAF SVPM SVLI SVPI -ILI -VAF -VVI	III TGI- SAFC AILC AILC VIV SMII SMII SVG SFII SVG	V IV SFDIG S	// FIFMS /LILLS /FITFS IFVFIS /LIFVS /LIFVS /LIAS VIGFS ILIASS /LIASS /LIASS	IAL 2 IVL 2 IL 2 IL 2 IL 2 IL 2 IL 2 IL 2 IL 2 I	221 222 222 222 222 222 222 222 222 221 221 221 221 221	TM6 PRLKVLS PRLKTLN ARFKAFN ARFKAFN ARHKALS ARHKALS ARLKALS ARLKALS ARLKALS	TCVS TCUS TCIA TCTA TCS TCS TCS TCS TCS TCS TCS TCS	ICAVI ISAVI ICVFI ICVFI ICVII ICVII ICVII ICVII ICVII ICVII ICVII	VI IIFYV LIFYV LQFYL LFYT LLFFI LLFYT LAFYL LAFYL LCFYT	VIII IX II I3 PVISI PMISV LAFFS PSFFT PSFFT PAFFS PALFS PALFS PAFFS	(AVI YRL FFTHRF(FFSHRF(FLTHRF(TLTORF(LLTHRF(FLTHRF(FMTHRF(FFTHRF(A 266 7 267 268 266 266 266 266 266 266 264 293	C b, d c, a, b c c c, r, e c, b c c c, a, b	
TM5 MOR8-2 MOR13-6 MOR22-2 MOR23-1 MOR31-2 MOR31-4 MOR31-6 MOR32-4 MOR32-5 MOR32-11 MOR33-1 MOR40-1	FNV INS INK VNI VNI VNI VNV VNV INI FNK	YGLI MYGLI ICGLI SYGLI WYGF WYGF LFGL- IYGL- IYGL- IYGL- IYGL	10 FVAL FIVI FVAF SVPM SVLI SVPI -ILI -VAF -VVI VAL	/// TGI- SAFC AILC AILC AILC SVI SMII SVG SHII SVG SHII	V IV SFDI SFDI LVDVF ULDV LLDV SMDV SSDI	// FIFMS /LILLS /FITFS /LIVFIS /LIFVS /LIAS /LIAS /LIAS /LIAS /LIATS /LIATS	ZAL 2 ZVL 2 ZIL 2	221 222 222 222 222 222 222 222 222 222	TM6 PRLKVLS PRLKTLN ARFKAFN ARFKALN ARHKALS ARHKALS ARLKALS ARLKALS ARLKALS ARLKALS	TCVS TCVS TCIA TCCA TCS TCS TCS TCS TCS TCS TCS TCS TCS	HCAVI HCVFI HCVFI HCVII HCVII HCVII HCVII HVCVII HCVII HFILII	VI IIFYV LIFYV LQFYL LFFI LLFFI LLFFI LAFYL LAFYL LCFYT LVFYI LFFST	VIII IX II I3 PVISI LAFFS LAFFS PSFFT PSFFT PAFFS PALFS PALFS PAFFS VILVI	(AVI YRL FFTHRF(FFSHRF(FLTHRF(LLTHRF(FLTHRF(FMTHRF(FFTHRF(VITNLA	A 266 7 267 268 266 273 267 266 266 266 266 264 293 293	C b, d c, a, b c c c, r, e c, b c c, a, b c, a, b	
TM5 MOR8-2 MOR13-6 MOR22-2 MOR23-1 MOR31-2 MOR31-4 MOR31-6 MOR32-4 MOR32-5 MOR32-11 MOR33-1 MOR40-1 MOR40-4	FNV INS INK VNI VNI VNV VNV INI FNK INS	SYGLI MYGLI ICGLI SYGLI WYGF WYGF LFGL- IYGL- IYGL IYGL LYQF INOLI	10 FVAL FIVI FVAF SVPM SVLI SVPI -ILI -VAF -VVI TVAL VIGW	III TGI- SAFC AILC AILC VMVJ SMII SVGJ SFII SVTC TLC	V -LDI STDI STDI STDI STDI UDVF UDVF UDVF UDVF UDVF SDI SSDI SSDI SSDI	// FIFMS /LILLS /FITFS /LIFVFIS /LIFVS /LIAS /LIAS /LIAS /LIAS /LIAS /LIAS /LIAS /LIAS	IAL 2 IVR 2 IIL 2 IL 2 IVL 2 IXL 2 IXL 2 IL 2 IL 2 IXL 2 IL 2 IL 2 IXL 2 IXL 2	221 222 222 222 222 222 222 222 222 221 221 221 221 221 221 221 221 221	TM6 PRLKVLS PRLKTLN ARFKAFN ARFKAFN ARHKALS ARHKALS ARLKALS ARLKALS ARLKALS ARLKALS AASKALS	TCVS TCVS TCIA TCCA TCSS TCSS TCSS TCSS TCSA TCSS TCSS	HCAVI HCVFI HVCFI HCVII HCVII HCVII HVCVII HVCVII HCVII FILII	VI IIFYV LIFYV LOFYL LEFI LLFI LAFYL LAFYL LAFYL LVFYI LFFST FFFYT	VIII IX IVIII IX PVISI PAFS PSFFT PSFFT PAFS PALFS PAFS VLLVL VIVVI	(AVI YRL FFTHRF(FFSHRF(FLTHRF(TLTORF(LLTHRF(FLTHRF(FMTHRF(FFTHRF(VITNLA SITHSV(A 266 7 267 268 266 273 266 266 266 266 264 293 267 270	C b, d c, a, b c c c, r, e c, b c c, a, b c, a, b c, a, b	
TM5 MOR8-2 MOR13-6 MOR22-2 MOR23-1 MOR31-2 MOR31-4 MOR31-6 MOR32-4 MOR32-5 MOR32-11 MOR33-1 MOR40-1 MOR40-4 MOR42-1	FNV INS INK VNI VNI VNV VNV INI FNK INS INS	YGLI MYGLI ICGLI SYGLI WYGF WYGF LFGL- IYGL- IYGL- IYGL LYQFV INQLI TAGL:	10 FVAL FIVI FVAF SVPN SVLI SVPI -ILI -VAF -VVI FVAL VIGW FLAW	III TGI- SAFC AIL ASU SMII SVG SHII SVG TIL SVG TIL SVG TIL SVG TIL SVG SHII SVG SVG SVG SVG SVG SVG SVG SVG SVG SVG		// FIFMS /LILLS /FITFS /LIFYS /LIFYS /LIAVS /LIAVS /LIAS /LIATS /LIATS /LIATS /LIATS /LIATS	IAL IVL IVR IIL IIL IIL IR	221 222 222 222 222 222 222 222 222 221 221 221 221 221 221 221 221 221 221 221	TM6 PRLKVLS PRLKTLN ARFKAFN ARFKAIN ARHKALS ARHKALS ARLKALS ARLKALS ARLKALS AVAKALS AASKALS	TCVS TCVS TCIA TCTA TCSS TCSS TCSS TCSS TCSS TCSS TCS	HCAVI HCVFI HCVFI HCVII HCVII HCVII HCVII HCVII HCVII HILII HILII HLLVII	VI I FYV LIFYV LFYV LFYI LFFI LFFI LFYT LAFYI LFFST FFYT FTVYS	VIII IX IVII IX PVISI PMISV LAFFS PSFFT PSFFT PAFFS PALFS PALFS VLLVL VIVVI STMSS	(AVI YRLA SMVHRFV FFTHRF(FLTHRF(LLTHRF(FLTHRF(FMTHRF(FTHRF(VITNLA SIVYRVA	A 266 7 267 268 266 266 266 266 266 266 264 293 267 267 270 4 269	C b, d c, a, b c c c, r, e c, b c c, a, b c, a, b c, a, b c, a, b	
TM5 MOR8-2 MOR13-6 MOR22-2 MOR23-1 MOR31-2 MOR31-4 MOR31-6 MOR32-4 MOR32-5 MOR32-11 MOR33-1 MOR40-1 MOR40-4 MOR42-1 MOR42-3	FNV INS INK VNI VNI VNV VNV VNV INI FNK INS LNK LNK	I YGLI MYGLI ICGLI SYGLI WYGF LFGL- IYGL- IYGL- IYGL IYGL INOLI INOLI TAGL	10 FVAL FIVI EVAF SVPI -ILI -VAF -VVI IVAL VIGW IIRT IVRI	III II SAFC AIL ASVI AIL SVI SVI SVI SVI SVI SVI SVI SVI SVI SVI		// FIFMS /LILLS /FITFS /LIFYS /LIAS /LIAS /LIAS /LIAS /LIAS /LIAS /LIAS /LIAS /LIAS /LIAS /LIAS	VAL 2 VVR 2 VIL 2	221 222 222 222 222 222 222 222 222 221 221 221 221 221 221 221 221 221 221 221 221 221 221 221 221 221 222 22 222 2	TM6 ERLKVLS ERLKTLN ARFKAFN ARFKAFN ARHKALN ARHKALS ARLKALS ARLKALS ARLKALS AQFRAFS AVAKALS ARSKALN ARSKALN	TCVS TCVS TCIA TCTA TCSS TCSS TCSS TCSS TCSS TCSS TCS	HCAVI HCVFI HCVFI HCVII HCVII HCVII HCVII HCVII HCVII HILII HFILII LLVII	VI IIFYV LIFYV LOFYL LEFI LEFI LAFY LAFY LAFY LAFYI LFST FFYT FFYYS FTVYS	VIII IX IVII IX PVISI PVISI PAFFS PSFFT PSFFT PAFFS PAFFS VLLVI VIVVI STMSS STMSS	AVIYRLA SMVHRFV FFTHRF(FFSHRF(FLTHRF(LLTHRF(FLTHRF(FMTHRF(FTHRF(SITNLA SIVYRVA SIVYRVA	A 266 7 267 268 266 266 266 266 266 266 264 293 267 267 270 A 269 A 269	C b, d c, a, b c c, r, e c, b c c, a, b c, a, b c, a, b d d	
TM5 MOR8-2 MOR13-6 MOR22-2 MOR23-1 MOR31-2 MOR31-4 MOR31-6 MOR32-4 MOR32-5 MOR32-11 MOR33-1 MOR40-1 MOR40-4 MOR42-3 MOR42-3 MOR103-15	FNV INS INK VNI VNI VNV VNV INI FNK INS INK INK FNK	YGLI YGLI SYGLI SYGLI WYGF LFGL- IYGL- IYGL- IYGL IYGL IYGL INQLI TAGL TYGL LT	10 P FVAL FIVI LVAF FVAF SVPI -ILI -VAF -VVI VIGW FLAW IIRT IVRI ILAI	III TGI- SAFC AIL ASVI AIL SVI SVI SVI SVI SVI SVI SVI SVI SVI SVI		// FIFMSY /LILLSY /FITFSY ALIGISY /LIFYSY /LIALSY /LIALSY /LIALSY /LIALSY /LIALSY /LIALSY /LIALSY /LIALSY /LIASY /LIASY /LIASY /LIASY	VAL 2 VVR 2 VIL 2 VIL 2 VVL 2 VIL 2	221 222 222 222 222 222 222 222 222 222	TM6 ERLKVLS ERLKTLN AREKAFN ARHKALN ARHKALN ARHKALS ARLKALS ARLKALS ARLKALS AVAKALS AASKALN ARSKALN ARSKALN	TCVS TCVS TCIA TCTA TCSS TCSS TCSS TCSS TCSS TCSS TCS	HCAVI HCVFI HCVFI HCVII HCVII HCVII HCVII HCVII HCVII HFILII LLVII HLVII HLVII	VI IIFYV LIFYV LOFYL LOFYL LEFI LAFY LAFY LAFY LAFY LAFYI LFST FFYT FFYY FTVYS IIFYA	VIII IX IVII IX PVISI PMISV LAFFS PSFFT PAFFS PAFFS VLLVI VIVVI STMSS STMSS ASIFI	Y AVI YR FFTHRFY FFSHRFY FLTHRFY LLTORFY LLTHRFY FLTHRFY FTHRFY VITNLA SIVYRVA SIVYRVA YARPKAI	A 266 7 267 268 266 266 266 266 266 266 264 293 267 203 267 270 4 269 4 269 4 269	C b, d c, a, b c c c, r, e c, b c c, a, b c, a, b c, a, b d d e, o, h, s, t	
TM5 MOR8-2 MOR13-6 MOR22-2 MOR23-1 MOR31-2 MOR31-4 MOR31-6 MOR32-4 MOR32-5 MOR32-11 MOR33-1 MOR40-1 MOR40-4 MOR42-3 MOR103-15 MOR106-1	FNV INS INK VNI VNI VNV INI INI INS INK INK INK INK INK	YGLI MYGLI ICGLI SYGLI WYGF LFGL- IYGL- IYGL- IYGL IYGL IYGL INOLI TAGL TYGL LTGF FIF <mark>2</mark> 2	10 FVAL FIVI FVAF SVPM SVLI SVPI -ILI -VAF -VVI VIGW FLAW IIRT IVRI ILAI AQSS	III TGI- SAFI AIL ASVI AIL SVI SVI SVI SVI SVI SVI SVI SVI SVI SVI		// FIFMS /LILLS /FITFS /LIFVFIS /LIFVS /LIAS /LIAS /LIAS /LIAS /LIAS /LIAS /LIAS /LIAS /LIAS /LIAS /LIAS /LIAS /LIAS /LIAS	VAL 2 VVR 2 VIL 2 VIL 2 VVL 2 VVL 2 VAL 2	221 222 222 222 222 222 222 222 222 221 2221 2221 2221 2221 2221 2221 2221 2221 2221 2221 2221 2221 2221 222 221 222 22 2	TM6 PRLKVLS PRLKTLN ARPKAFN ARPKAFN ARHKALN ARHKALS ARLKALS ARLKALS ARLKALS ARSKALS ARSKALS ARSKALS GRRKAFS	TCS TCS TCS TCS TCS TCS TCS TCS TCS TCS	IICAVI IICVFI IVVFI IVCIII IVCIII IVCUII IVCVII IVCVII IVCVII IICVII IICVII ILLVII ILLVII ILVVV	VI IIFYV LIFYV LFYV LFYV LFFY LFFY LAFY LAFY LAFY LAFY LAFY LAFY IFYY TVYS TVYS IIFYA SLFYG	VIII IX IVIII IX PVISI PMISV LAFFS PSFFT PAFFS PAFFS VLLVI VILVI STMSS STMSS ASIFI	Y AVIYRLA SMVHRFY FFTHRFY FLTHRFY TLTORFY LLTHRFY FLTHRFY FMTHRFY SITHSY SIVYRVA SIVYRVA YARPKAI YVSPTY	A 266 7 267 268 266 266 266 266 266 266 264 293 267 270 A 269 A 269 269 2 269 2 272	C b, d c, a, b c c c, r, e c, b c c, a, b c, a, b c, a, b d d e, o, h, s, t c, b	
TM5 MOR8-2 MOR13-6 MOR22-2 MOR23-1 MOR31-2 MOR31-4 MOR31-6 MOR32-4 MOR32-5 MOR32-11 MOR33-1 MOR40-1 MOR40-4 MOR42-1 MOR42-3 MOR103-15 MOR106-1 MOR106-1 MOR106-1 MOR106-1	FNV INS INK VNI VNI VNV INI VNV INI INI INS INS INS INS INS INS INS INS	YGLI MYGLI ICGLI SYGLI WYGF LFGL- IYGL- IYGL- IYGL IYGL IYGL INOLI TAGL ITGF FIFY LYFS	10 FVAL FIVI SVPM SVLI SVPI -ILI -VAF -VVI VIGW FLAW IIRT TVBI ILAI AQSS ILSP	III III SAF AIL AIL AIL AIL AIL AIL SVI SVI SVI SVI SVI SVI SVI SVI SVI SVI		// FIFMS /LILLS /FITFS /LIFVFIS /LIFVS /LIAS /LIAS /LIAS /LIAS /LIAS /LIAS /LIAS /LIAS /LIMS /LIMS /LIGS /FIMGS	VAL 2 VVR 2 VIL 2 VVL 2 VVL 2 VVL 2 VZL 2 VZL 2 VZR 2 VZ VZ VZ VZ VZ VZ VZ VZ VZ VZ VZ VZ VZ	221 222 222 222 222 222 222 222 222 221 221 221 221 221 221 222 221 222 221 222 221 222 221 222 221 222 221 222 22 2	TM6 PRLKVLS PRLKTLN ARPKAFN ARPKAFN ARHKALN ARHKALS ARLKALS ARLKALS ARLKALS ARSKALS ARSKALS GRRKAFS GRRKAFS	TCS TCS TCS TCS TCS TCS TCS TCS TCS TCS	IICAVI IICVFI IVVFI IVCIII ICVII IVCVII IVCVII IVCVII IICVII IICVII ILLVII ILLVII ILVVV ILAVV	VI I FYV LIFYV LFYV LFYI LFFI LFFY LAFY LAFY LAFY LAFY LAFY LFFST FFYY FFYY STVYS LFFS FFYY LFFS FFYY LFYA LFYG ALFYG	VIII IX IVIII IX PVISI PMISV LAFFS PSFFT PAFFS PAFFS VLLVI VIVVI STMSS STMSS ASIFI FVMVM SVLVM	AVIYRLA SMVHRFV FFTHRF(FFSHRF(FLTHRF(TLTORF(LLTHRF(FLTHRF(FMTHRF(SITHSV(SIVYRVA SIVYRVA SIVYRVA YARPRAI YVSPTY(YGSPTS	A 266 7 267 268 266 266 266 266 266 266 264 293 267 270 A 269 4 269 269 272 266	C b, d c, a, b c c c, r, e c, b c c, a, b c, a, b c, a, b d d e, o, h, s, t c, b a	
TM5 MOR8-2 MOR13-6 MOR22-2 MOR23-1 MOR31-2 MOR31-4 MOR31-6 MOR32-4 MOR32-5 MOR32-11 MOR32-11 MOR40-1 MOR40-1 MOR40-4 MOR42-3 MOR103-15 MOR106-1 MOR106-13P MOR118-1	FNV INS VNI VNI VNV VNV FNK FNK LNK LNK LNK LNK LNK LNK LNK LNK LNK L	YGLI YGLI SYGLI SYGLI WYGF UYGF LFGL- IYGL- IYGL- IYGL- IYGL IYGL- IYGL IYGL INOLI TVGL FFF FFF FFF	10 FVAL FIVI FVAF SVPM SVLI VI VI TVAL FVAL FVAL FLAW FLAW FLAW FLAW FLAW FLAW FLAW FL	III III AIL AIL ASVI SMII SVG SMII SVG SMII SVG SMII SVG SMII SVG SMII SVG SMII SVG SMII SVG SMII SVG SMII SVG SMII SVG SMII SVG SMII SVG SS SS SS SS SS SS SS SS SS SS SS SS SS	V IV STDI S	// FIFMS //IILS //IIFS //IFVFIS //IFVFIS //IFVS //IFVS //IAS //IAS //IAS //IAS //IAS //IAS //IAS //IAS //IAS //IAS	VAL 2 VVR 2 VVR 2 VTL 2 VTL 2 VVL 2 VVL 2 VVL 2 VIL 2	221 222 222 222 222 222 222 222 222 221 221 221 221 221 221 222 226 224 222 226 224 225 230 224 218	TM6 PRLKUS PRLKTLN ARFKAFN ARFKAFN ARHKALN ARHKALS ARLKALS ARLKALS ARLKALS ARSKALS GRRKAFS GRRKAFS GRRKAFS GRRKAFS	TCS TCS TCS TCS TCS TCS TCS TCS TCS TCS	IICAVI IICVFI IIVVFI IICVII IICVII IICVII IICVII IICVII IICVII IICVII IILIII ILLVII ILVVI IIVVV IIIVV	VI I FYV LIFYV LFYV LFYI LFFI LFFI LFFT LAFY LAFFT LFFST FFYT FFYY LFFST FFYY LFFST IFYA LFYG LFYG LFYG LFYG	VIII IX IVIII IX PVISI PMISV LAFFS PSFFT PGIFT PAFFS PAFFS PAFFS VILVI VIVVI STMSS STMSS STMSS STMSS STMSS STMSS STMSS STMSS STMSS	Y AVIYRLA SMVHRFY FFTHRF(FFSHRF(TLTQRF(LLTHRF(FLTHRF(FFTHRF(SITHSV(SIVYRVA SIVYRVA SIVYRVA YARPKAI YVSPTY(YGSPTS	A 266 7 267 268 266 266 266 266 266 266 264 270 A 269 269 269 269 269 272 266 266 269 269 269 269 269 269	C b, d c, a, b c c c, r, e c, b c c, a, b c, a, b c, a, b d d e, o, h, s, t c, b a h	
TM5 MOR8-2 MOR13-6 MOR22-2 MOR23-1 MOR31-2 MOR31-4 MOR31-6 MOR32-4 MOR32-4 MOR32-5 MOR32-11 MOR40-1 MOR40-1 MOR40-4 MOR42-3 MOR103-15 MOR106-13P MOR118-1 MOR136-6	FNV INS VNI VNI VNV VNV INI FNK INS LNK LNK LNK LNK LNK ITS LI LI INS	YGLI YGLI SYGLI SYGLI WYGF UYGF LFGL- IYGL IYGL IYGL IYGL INOLI TAGL LYF FIFY LVFS FLGF LVIL	10 FVAL FIVI FVAF SVPM SVLI VVI VVI TVAL TVAL TVAL TVAL TVAL TVAL TVAL TVAL	III III III III III III III III	V IV STDI	// FIFMS //IILS //IIFS //IFVFIS //IFVFIS //IFVS //IFVS //IAS //IAS //IAS //IAS //IAS //IAS //IAS //IAS //IAS //IAS //IAS //IAS	VAL 2 VVR 2 VVR 2 VTL 2 VTL 2 VVL 2 VVL 2 VVL 2 VIL 2	221 222 222 222 222 222 222 222 221 221	TM6 PRLKVLS PRLKTLN ARFKAFN ARFKAFN ARHKALN ARHKALS ARLKALS ARLKALS ARLKALS ARLKALS ARSKALS GRRKAFS GRRKAFS GRRKAFS GRRKAFS	TCSS TCSS TCSS TCSS TCSS TCSS TCSS TCSS	ILCAVI ICAVI ICVFI ICVFI ICVTI ICVII ICVII ICVII ICVII ICVII ICVII ICVII ICVII ICVII ICVII ICVII ICVV ICVV	VI I FYV LIFYV LFYV VFYI LFFI LFFI LFFT LAFY LAFFT LAFY LFFST FFYY FFYY SLFYG LFYG LFYG LFYG LFYG LFYG LFYG LFYG LFYG LFYG LFYG	VIII IX IVIII IX PVISI PMISV LAFFS FFT PGIFT PAFFS PAFFS PAFFS PAFFS VILVI VIVVI STMSS STMSS STMSS STMSS STMSS STMSS STMSS STMSS STMSS STMSS	AVIYRLA SMVHRFV FFTHRF(FFSHRF(FLTHRF(FLTHRF(FLTHRF(FHTHRF(FFTHRF(SIVYRVA SIVYRVA SIVYRVA YARPKAI YVSPTY(YGSPTS YVRSGK AFFPSSI	A 266 7 267 268 266 266 266 266 266 266 264 270 A 269 269 269 269 269 269 269 269 269 269	C b, d c, a, b c c c, r, e c, b c c, a, b c, a, b c, a, b d d e, o, h, s, t c, b a h	
TM5 MOR8-2 MOR13-6 MOR22-2 MOR23-1 MOR31-2 MOR31-4 MOR31-6 MOR32-4 MOR32-5 MOR32-11 MOR33-1 MOR40-1 MOR40-1 MOR40-4 MOR42-3 MOR103-15 MOR106-13P MOR118-1 MOR136-6 MOR171-2	FNV INK VNI VNI VNV VNV FNK FNK LNK LNK LNK LNK LNK LNK LNK LNK LNK L	YGLI YGLI SYGLI SYGLI WYGF UYGF LFGL- IYGL IYGL IYGL IYGL IYGL INOLI TVGL LYF FIFY LVFS FLGF LVIL MAVFI	10 FVAL FIVI FVAF SVPM SVLI VIGW FLAI FVAL FVAL FLAI AQSS ILSP VIAN FLAQ	III TGI- SAFC AIL AIL ASVI SVI SVI SVI SVI SVI SVI SVI	V IV SFDI SFDI SFDI SFDI SFDI UDVI UDVI SDI SSDI	// FIFMS //IILS /FIFS //IFVFIS //IFVFIS //IFVS //IAS //IAS //IAS //IAS //IAS //IAS //IAS //IAS //IAS //IAS //IAS //IAS //IAS //IAS	VAL 2 VVR 2 VVR 2 VTL 2 VTL 2 VVL 2 VVL 2 VVL 2 VIL 2	221 222 222 222 222 222 222 222 222 221 221 221 221 221 221 221 221 221 222 226 224 222 226 224 225 230 224 218 220 219	TM6 PRLKUS PRLKTLN ARFKAFN ARFKAFN ARHKALN ARHKALN ARHKALS ARLKALN ARLKALS ARLKALS ARSKALS GRRKAFS GRRKAFS GRRKAFS GRSKAFS GRSKAFS	TCSS TCSS TCSS TCSS TCSS TCSS TCSS TCSS	IICAVI IICVFI IIVVFI IICVII IICVII IICVII IICVII IICVII IICVII IICVII IILIII ILLVII ILVVI IIVVV IIVVV IIVVV	VI I FYV LIFYV LFYV VFYI LFFI LFFI LFFT LAFY LAFFT LAFY LFFST FFYT SIFYA SLFYG SLFYG SLFYG SLFYG	VIII IX PVISI PVISI PAFS PSFFT PGIFT PAFS PAFS PAFS PAFS PAFS VILVI VIVVI STMSS STMS	Y AVIYR FFTHRFY FFSHRFY FLTHRFY LTQRFY LLTHRFY FLTHRFY FFTHRFY SIYRVA SIYYRVA SIYYRVA YARPKAI YVSPTYY YRSPTS YVRSGX YFFPSSI YLKPSTA	A 266 7 267 268 266 266 266 266 266 266 266 269 270 A 269 270 A 269 272 266 269 272 266 269 272 266 269 272 266 269 272 266 269 273	C b, d c, a, b c c c, r, e c, b c c, a, b c, a, b c, a, b d d e, o, h, s, t c, b a h j k, g	
TM5 MOR8-2 MOR13-6 MOR22-2 MOR23-1 MOR31-2 MOR31-4 MOR31-6 MOR32-4 MOR32-4 MOR32-5 MOR32-11 MOR40-1 MOR40-1 MOR40-4 MOR42-3 MOR103-15 MOR106-13P MOR106-13P MOR118-1 MOR136-6 MOR171-2 MOR174-4	FNV INS VNI VNI VNI VNV VNV INI FNK INS LNK LNK LNK LNK LNK INS I I I I I I I I I I I I I I I I I I	YGLI MYGLI ICGLI SYGLI WYGF UYGF IYGL- IYGL- IYGL IYGL IYGL IYGL IYGL INOLI TGCI FIFY LYFS FLGF LVIL MAVFI LLLF	10 FVAL FIVI FVAF SVPM SVLI SVPI -ILI -VAF -VVI TVAL VIGW FLAW ILAI AQSS ILSP VIAN FLAV FLAQ	III TGI- SAFC AIL AIL ASVI AIL SVI SVI SVI SVI SVI SVI SVI SVI	V IV SFDI SFDI SFDI SFDI SFDI V SFDI V V V V V V SSDI	// FIFMS /LILLS /FIFS /LICTS /LICTS /LIACS /LIACS /LIASS /LIASS /LIASS /LIASS /LIASS /LIASS /LICS /FIMGS /FIMGS /FIMGS /FIMGS /FIMGS /FIMGS	VAL 2 VVR 2 VVR 2 VTL 2	221 222 222 222 222 222 222 222 222 221 221 221 221 224 224	TM6 PRLKUS PRLKTLN ARFKAFN ARFKAFN ARHKALN ARHKALN ARHKALS ARLKALN ARLKALS ARLKALS ARSKALN GRHKAFS GRRKAFS GRRKAFS GRSKAFS GRRKAFS GRRKAFS GRRKAFS	TCSS TCSS TCSS TCSS TCSS TCSS TCSS TCSS	IICAVI IICVFI IIVVFI IICVII IICVII IICVII IICVII IICVII IICVII IICVII IILIII ILLVII ILVVI IIVV IICVVI IIVV IICVVI IIVV	VI I FYV LIFYV LFYV VFYI LFFI LFFI LFFT LAFY LAFFT LAFY LFFST FFYY SIFYA SLFYG SLFYG SLFYG IFF	VIII IX PVISI PVISI PAFS PSFFT PGIFT PAFS PAFS PAFS PAFS PAFS VILVI VIVVI STMSS STMS	AVIYRLA SMVHRFV FFTHRF(FFSHRF(FLTHRF(TLTQRF(LLTHRF(FLTHRF(FHTHRF(SIVYRVA SIVYRVA SIVYRVA SIVYRVA YARPKAI YVSPTY(YGSPTS YVRSGK XFFPSSI YLKPSTA	A 266 7 267 268 266 266 266 266 266 266 266 269 270 A 269 270 A 269 272 266 269 272 266 269 272 266 269 272 266 269 272 266 269 272 266 269 273	C b, d c, a, b c c c, r, e c, b c c, a, b c, a, b c, a, b d d e, o, h, s, t c, b a h j k, g m, n	
TM5 MOR8-2 MOR13-6 MOR22-2 MOR23-1 MOR31-2 MOR31-4 MOR31-6 MOR32-4 MOR32-5 MOR32-11 MOR32-11 MOR40-1 MOR40-1 MOR40-4 MOR42-3 MOR103-15 MOR106-13P MOR106-13P MOR118-1 MOR136-6 MOR171-2 MOR174-4 MOR174-9	FNV INS VNI VNI VNI VNV VNV INI FNK INS INS INS INS INS INS INS INS INS INS	YGLI YGLI SYGLI SYGLI WYGF UYGF LFGL- IYGL IYGL IYGL IYGL IYGL IYGL FICF FIFY LVFS FICF LVIL MAVFI LLLF	10 FVAL FIVI FVAF SVPM SVLI SVPI -ILI VVAL VIGW FLAW FLAW FLAW FLAW FLAW FLAW FLAG	II TGI- SAFC AIL AIL AIL AIL SVI SVI SVI SVI SVI SVI SVI SVI	V IV IV IV IV IV IV IV IV IV I	// FIFMS //IILS //IIFS //IFVFIS //IFVS //IFVS //IACS //IACS //IACS //IACS //IACS //IACS //IACS //FIMGS /	VAL 2 VVR 2 VVR 2 VTL 2	221 222 222 222 222 222 222 222 222 221 221 221 221 224 224	TM6 PRLKUS PRLKTLN ARFKAFN ARFKAFN ARHKALN ARHKALN ARHKALS ARLKALN ARLKALS ARLKALS ARSKALN GRRKAFS GRRKAFS GRRKAFS GRRKAFS GRRKAFS GRRKAFS GRRKAFS GRRKAFS	TCSS TCSS TCSS TCSS TCSS TCSS TCSS TCSS	ILCAVI ICVFI IVVFI IVVFI ICVII IVCIII ICVII IVCVII ICVII ICVII ICVII ILIII ILIII ILIII ILVVI ILVVI ILVVI ILVVI ILAVI ILAII	VI I FYV LIFYV LFYV LFYV LFYV LFFT LFFT LAFY LAFFT LAFYL LFFST FFVYS LFFST FFVYS LFYG LFYC LFYV LAFFT LFYV LAFT LFYV LAFT LFYV LAFT LFYV LAFT LFYV LAFT LFYV LAFT LFYV LAFT LFYV LAFT LFYV LAFT LAFT LFYV LAFT LATT	VIII IX PVISI PVISI PAFS PSFFT PGIFT PAFS PAFS PAFS PAFS PAFS VILVI VIVVI STMSS STMSS STMSS STMSS STMSS STMSS STMSS STMSS STMSS TIFI TVMVM SVLVM SVLVM SVLVM SVLVM SVLVM SVLVM SVLVM	AVIYRLA SMVHRFV FFTHRF(FFSHRF(FLTHRF(FLTHRF(FLTHRF(FHTHRF(FHTHRF(SITHSV(SIVYRVA SIVYRVA SIVYRVA YARPKAI YVSPTY(YGSPTS YVRSGK YFFPSSI YLKPSTA	266 267 268 267 266 266 266 266 266 266 267 266 267 266 267 266 267 267 267 267 267 267 267 267 269 269 266 266 266 267 266 267 269 266 266 266 266 266 266 266 266 266 266 266 266 266 266 266 266 266 266	C b, d c, a, b c c c, r, e c, b c, a, b c, a, b c, a, b d d e, o, h, s, t c, b a h j k, g m, n i, m, n	
TM5 MOR8-2 MOR13-6 MOR22-2 MOR23-1 MOR31-2 MOR31-4 MOR31-6 MOR32-4 MOR32-5 MOR32-11 MOR40-1 MOR40-1 MOR40-4 MOR42-1 MOR42-3 MOR103-15 MOR106-13P MOR106-13P MOR118-1 MOR136-6 MOR171-2 MOR174-4 MOR175-1	FNV UNK VNI VNI VNV VNV VNV INI FNK INS LNK LNK LNK LNK LNK INS UNK VSO MNK	YGLI MYGLI ICGLI SYGLI WYGF WYGF LFGL- IYGL IYGL IYGL IYGL IYGL IYGL INOLI TGCI FIFY LVFS FLGF LVIL MAVFI LLLF CLLF	10 FVAL FIVI FVAF FVAF SVPI -ULI -ULI -VAF -VVI ILAI ILAI AQSS ILSP VIAN FLAV FLAV FLAV FLAV FLAV FLAV FLAV FLAV	II TGI- SATL AIL AIL AIL AIL SVI SVI SVI SVI SVI SVI SVI SVI	V IV IV IV IV IV IV IV IV IV I	// FIFMS //IILS //IIFS //IFVFIS //IFVS //IFVS //IACS	VAL 2 VVR 2 VVR 2 VTL 2	221 222 222 222 222 222 222 222 221 221	TM6 PRLKUS PRLKTLN ARFKAFN ARFKAFN ARHKALN ARHKALN ARHKALS ARLKALN ARLKALS ARLKALS ARLKALS ARSKALN GRRKAFS GRRKAFS GRRKAFS GRRKAFS GRRKAFS GRRKAFS GRRKAFS GRRKAFS GRRKAFS GRRKAFS GRRKAFS GRRKAFS	TCSS TCSS TCSS TCSS TCSS TCSS TCSS TCSS	ILCAVI ICVFI IVVFI ICVII ICVII ICVII ICVII ICVII ICVII ICVII ICVII ILIII ILIII ILVVI ILVVI ILVVI ILVVI ILVVI ILAVI ILAII ILAII ILAII	VI I FYV LIFYV LFYV LFYI LFYI LFFI LFFI LFYS LFFST FFVYS LFFST FFVYS LFYS	VIII IX PVISI PVISI PAFS PSFFT PGIFT PAFS PAFS PAFS PAFS PAFS VILVI VIVVI STMSS STMSS STMSS STMSS STMSS STMSS STMSS STMSS STMSS STMSS TIFI TUFFI	Y AVIYR FFTHRFY FFTHRFY FLTHRFY LTQRFY LLTYRFY FLTHRFY FFTHRFY FFTHRFY SITHSVY SIVYRVZ SIVYRVZ SIVYRVZ YARPKAI YVSPTYY YARPKAI YVRSGX YYRSSX YVRSX YVRSSX YVRSSX YVRSSX YVRSSX YVRSSX YVRSSX YVRSSX YVRSSX YVRSSX YVRSSX YVRSSX YVRSSX YVRSSX YVRSSX YVRSSX YVRSSX YVRSSX YVRSSX YVRX YVRX YVRX YVRX YVRX YVRX YVRX YVR	266 267 266 273 266 266 266 266 266 266 267 266 267 266 267 266 267 266 267 267 267 267 267 267 269 269 266 266 266 267 269 266 266 266 266 266 266 266 266 266 266 266 266 266 266 266 266 266 266 266 266 266 266	C b, d c, a, b c c c, r, e c, b c, a, b c, a, b c, a, b d d e, o, h, s, t c, b a h j k, g m, n i, m, n f, e	
TM5 MOR8-2 MOR13-6 MOR22-2 MOR23-1 MOR31-2 MOR31-4 MOR31-6 MOR32-4 MOR32-5 MOR32-11 MOR32-11 MOR40-1 MOR40-1 MOR40-4 MOR42-3 MOR103-15 MOR106-13P MOR106-13P MOR118-1 MOR136-6 MOR171-2 MOR174-4 MOR175-1 MOR203-1	FNV UNK VNI VNI VNV VNV VNV VNV INI FNK INS LNK LNK LNK LNK LNK LNK LNK LNK LNK LNK	IYGLI MYGLI ICGLI SYGLI WYGF UYGF IYGL- IYGL- IYGL IYGL IYGL IYGL IYGL IYGL INOLI TGCI FIFY INOLI FIFY LUFS FLGF LVIL MAVFI LLF MVLT	10 FVAL FIVI FVAF FVAF SVPI -ULI -ULI -VAF -VVI ILI ILAI AQSS ILSP VIAN FLAV FLAV FLAV ILAY ILA	III SVG SMI SVG SVG SVG SVG SVG SVG SVG SVG SVG SVG	V IV IV IV IV IV IV IV IV IV I	// FIFMS /LILLS /FIFS /LICTS /LICTS /LIAS	YAL 2 YVR 2 YVR 2 YTL 2 YTT 2	221 222 222 222 222 222 222 222 222 221 221 221 224 224	TM6 PRIKUS PRIKTIN ARFKAFN ARFKAFN ARHKAIN ARHKAIN ARHKAIN ARHKAIN ARHKAIN ARIKAIN ARIKAIN ARIKAIN GRRKAFS	TCSS TCSS TCSS TCSS TCSS TCSS TCSS TCSS	ILCAVI ICVFI IVVFI ICVII ICVII IVCIII ICVII ICVII ICVII ICVII ICVII ILIII ILIII ILVVI ILVVI ILVVI ILVVI ILVVI ILAII ILTAI ILTAI	VI I FYV LIFYV LFYV LFYV LFYV LFFT LFFT LAFY LAFT LAFYV LAFT FFVY FFVYS LFFST FFVYS LFYG	VIII IX IVIII IX PVISI PAFS PSFFT PGIFT PAFS PAFS PAFS PAFS PAFS VILVI VIVVI STMSS STMSS STMSS STMSS STMSS STMSS STMSS STMSS STMSS TILFI TILFI TILFI TILFI TILFI TILFI	AVIYRLA SMVHRFV FFTHRF(FFSHRF(FLTHRF(FLTHRF(FLTHRF(FLTHRF(FHTHRF(FFTHRF(VITNLA SIVYRVA SIVYRVA SIVYRVA YARPKAI YVSPTY(YSPTY(YFFPSSI YVRSGA YFFPSSI YVRSGA YVRSSA YVRSSA YVRSSA YVRSSA YVRSSA	266 267 266 267 266 266 266 266 266 266 266 266 266 266 267 266 267 266 267 266 267 266 267 269 269 266 265	C b, d c, a, b c c c, r, e c, b c, a, b c, a, b c, a, b d d e, o, h, s, t c, b a h j k, g m, n i, m, n f, e c	
TM5 MOR8-2 MOR13-6 MOR22-2 MOR23-1 MOR31-2 MOR31-4 MOR31-6 MOR32-4 MOR32-5 MOR32-11 MOR32-11 MOR40-1 MOR40-1 MOR40-4 MOR42-3 MOR103-15 MOR106-13P MOR106-13P MOR118-1 MOR136-6 MOR171-2 MOR174-4 MOR175-1 MOR203-1 MOR203-1 MOR204-32	FNV UNK VNII VNII VNII VNV VNV VNV VNV VNV VNV	IYGLI MYGLI ICGLI SYGLI WYGF UYGF IYGL- IYGL- IYGL IYGL IYGL IYGL IYGL IYGL ITGF IYGL INOLI TGF IYGL INOLI TGF IYGL INOLI TGF TGF TGF TGF TGF TGF TGF TGF TGF TGF	10 FVAL FIVI FVAF FVAF SVPI -UII -UII VIGW FLAW FLAW FLAW FLAW FLAW FLAW IIST ILAI ILAI FLAV FLAV FLAV IIST ILAI ILAI FLAV IIST ILAI	III SVG SMII SVG SMII SVG SMII SVG SMII SVG SMII SVG SMII SVG SMII SVG SMII SVG SMII SMII SMII SMII SMI SMI SMI SMI SMI	V IV IV IV IV IV IV IV IV IV I	// FIFMS //IILS //IIFS //IFVFIS //IFVS //IALS //IAS //IAS //IAS //IAS //IAS //IAS //IAS //ILS //ILS //ILS //ILS //IALS //IALS	YAL 2 YVR 2 YVR 2 YTL 2 YTT 2	221 222 222 222 222 222 222 222 222 221 221 221 222 224 224	TM6 RLKUS RLKUS ARFKAFN ARFKAFN ARFKAFN ARHKALS ARHKALS ARLKALS ARLKALS ARLKALS ARSKALS GRRKAFS GR	TCSS TCSS TCSS TCSS TCSS TCSS TCSS TCSS	ILCAVI ILCVII IVVFI IVVII IVVII IVCIII IVCVII IVCVII IVCVII ILCVII ILCVII ILILII ILLVII ILVVI ILVVV ILVVV ILAVI ILTAV ILTAV	VI I FYV LIFYV LFYV LFY LFY LFFT LFFT LAFY LAFT LAFY LAFT LAFY LAFT LAFY LFFST FFVY LFFST FFVY LFYG LF	VIII IX IVIII IX PVISI PMISV LAFFS PSFFT PGIFT PAFFS PALFS PALFS PALFS VILVI VIVVI STMSS STMSS STMSS STMSS STMSS STMSS STMSS STMSS TILFI TILFI TILFI TILFI TILFI TILFI TILFI TILFI	AVIYRLA SMVHRFV FFTHRF(FFSHRF(FLTHRF(FLTHRF(FLTHRF(FLTHRF(FHTHRF(FHTHRF(SITHSV(SIVYRVA SIVYRVA YARPKAI YVRSFTA YVRSGKI YFFPSSI YVRSGKI YFFPSSI YVRSGKI YVRSGKI YVRSSK YV	266 267 266 267 266 266 266 266 266 266 267 266 267 266 267 266 267 266 267 266 267 266 267 266 267 266 266 266 266 267 266 267 266 266 266 266 266 266 266 266 266 266 266 266 266 266 266 265 265 295	C b, d c, a, b c c c, r, e c, b c, a, b c, a, b c, a, b d d e, o, h, s, t c, b a h j k, g m, n i, m, n f, e c a	
TM5 MOR8-2 MOR13-6 MOR22-2 MOR23-1 MOR31-2 MOR31-4 MOR31-6 MOR32-4 MOR32-5 MOR32-11 MOR32-11 MOR40-1 MOR40-1 MOR40-4 MOR42-3 MOR103-15 MOR106-13P MOR106-13P MOR118-1 MOR136-6 MOR171-2 MOR174-4 MOR175-1 MOR203-1 MOR203-1 MOR204-32 MOR258-5	FNV UNK VNII VNII VNII PNT FNK INS INS INS INS INS INS INS INS INS INS	YGLI YGLI SYGLI SYGLI WYGF UFGL- IYGL- IYGL- IYGL- IYGL IYGL IYGL IYGL IYGL IYGL IYGL IYGL	10 FVAL FIVI FVAF FVAF SVPI -VII VIGW FLAW FLAW FLAW FLAW FLAW FLAW FLAW IIST ILAI ILAI FLAV FLAV IIST ILAI ILAI FLAV IIST ILAI IL	II TGI- SATI AIL AIL AIL AIL SVG SVI SVI SVI SVI TIL SVI FIL FIL FIL FIL FIL FIL FIL FI	V IV IV IV IV IV IV IV IV IV I	// FIFMS //IILS //IIFS //IFVFIS //IFVS //IAS //IAS //IAS //IAS //IAS //IAS //IAS //IAS //IAS //ILS //ILS //ILS //IAS	YAL 2 YVR 2 YVR 2 YTL 2 YTT 2	221 222 222 222 222 222 222 222 222 222	TM6 RLKUS RLKUS ARFKAFN ARFKAFN ARFKAFN ARHKALS ARHKALS ARHKALS ARLKALS ARLKALS ARSKALS ARSKALS GRRKAFS GRRKFS GRRKAFS GRRKFS GRRKFS GRRKFS GRRKFS GRRKFS GRRKFS	TCSS TCSS TCSS TCSS TCSS TCSS TCSS TCSS	ILCAVI ILCAVI ILCVII IVVII IVVII IVCIII IVCIII IVCVII IVCVII IVCVII ILCVII ILCVII ILLVII ILLVII ILLVII ILLVII ILVVI ILVVV ILAXI ILTAVI ILTAVI ILTAVI	VI I FYV LIFYV LFYV LFY LFY LFFI LFFT LAFY LAFT LAFY LAFY LAFY LAFY LAFY LFY FTVY LFFST IFY LFY LFY LFY LFY LFY LFY LFY L	VIII IX IVIII IX PVISI PMISV LAFFS PSFFT PGIFT PAFFS PAFFS PAFFS PAFFS PAFFS VILVI VIVVI STMSS STMSS STMSS STMSS STMSS STMSS STMSS STMSS STMSS STMSS STMSS STMSS STMSS STMSS STAFM TILFI TILFI TILFI TILFI TILFI TILFI TILFI TILFI TILFI TILFI	Y AVIYR FFTHRFY FFTHRFY FLTHRFY FLTHRFY FLTHRFY FLTHRFY FHTHRFY FFTHRFY YITNLA SITYRVZ YARPKAI YVRSFY YVRSGX YVRSGX YFFPSSI YVRSGX YFFPSSI YVRSGX YVRSGX YVRSSX YVRSX YVRX YVRSX YVRX YVRX YVRX YVRX YVRX YVRX YVRX YVR	266 267 266 267 266 266 266 266 266 266 267 266 267 266 267 266 267 266 267 267 267 269 269 266 266 266 266 266 267 267 266 267 266 266 266 266 266 266 266 266 266 266 266 266 266 265 265 265 265 265 265 265 265 2	C b, d c, a, b c c c, r, e c, b c, a, b c, a, b c, a, b c, a, b d d e, o, h, s, t c, b a h j k, g m, n i, m, n f, e c a q, l, g, v, w	
TM5 MOR8-2 MOR13-6 MOR22-2 MOR23-1 MOR31-2 MOR31-4 MOR31-6 MOR32-4 MOR32-5 MOR32-11 MOR40-1 MOR40-1 MOR40-4 MOR42-1 MOR42-3 MOR103-15 MOR106-13P MOR106-13P MOR118-1 MOR136-6 MOR171-2 MOR174-4 MOR175-1 MOR175-1 MOR203-1 MOR203-1 MOR204-32 MOR258-5 MOR267-13	FNV UNK UNK VNII VNII VNII PNK VNV VNV VNV PNK LNK LNK LNK LNK LNK LNK LNK LNK LNK L	YGLI YGLI SYGLI SYGLI WYGF UYGF IYGL- IYGL- IYGL IYGL- IYGL IYGL IYGL IYGL IYGL IYGL IYGL IYGL	10 FVAL FIVI FVAF SVPM SVLI SVPI -UXI VIGW FLAW FLAW FLAW FLAW FLAW FLAV IIST ILAI IL	II TGI- SATI AIL AIL AIL AIL AIL SVG SVI SVI SVI SVI TIL SVI FIL FIL FIL FIL FIL FIL FIL FI	V IV IV IV IV IV IV IV IV IV I	// FIFMS //IILS //IIFS //IFVFIS //IFVS //IASS //IASS //IASS //IASS //IASS //IASS //IASS //IASS //IASS //ILS //ILS //ILS //ILS //ILS //IASS //ILS //ILS //IASS //ILS //ILS //IASS //ILS //ILS //IASS //ILS //ILS //ILS //IASS //ILS //ILS //ILS //ILS //ILS //ILS //ILS //ILS //ILS //ILS //ILS //ILS //ILS	YAL 2 YVR 2	221 222 222 222 222 222 222 222 222 222	TM6 RLKUS RLKUS ARFKAFN ARFKAFN ARFKAFN ARHKALS ARHKALS ARHKALS ARLKALS ARLKALS ARSKALS AVAKALS ARSKALS GRRKAFS GRFKAFS GRRKFS GRRKAFS GRRKAFS GRRKFS GRRKFS GRRKFS GRRKFS GRRKFS	TCSS TCSS TCSS TCSS TCSS TCSS TCSS TCSS	ILCAVI ILCAVI ILCVII IVVII IVVII IVVII IVVII IVVII ILCVII ILIII ILIII ILIII ILVVI ILVVI ILAVI ILAVI ILTAVI ILTAVI ILTAVI	VI I FYV LIFYV LIFYV LFYI LFFI LFFI LFFT LAFY LAFT LAFT	VIII IX PVISI PVISI PVISI PAFFS PSFFT PSFFT PAFFS PAFFS PAFFS PAFFS PAFFS VILVI VIVVI STMSS STMSS STMSS STMSS STMSS STMSS STMSS STMSS STMSS STMSS STMSS STMSS STMSS STMSS STAFM TILFI TILFI TILFI TILFI TILFI TILFI TILFI TILFI TILFI TILFI TILFI TILFI TILFI	AVIYRLA SMVHRFV FFTHRF(FFSHRF(FLTHRF(FLTHRF(FLTHRF(FLTHRF(FMTHRF(FMTHRF(FMTHRF(FMTHRF(FMTHRF(FMTHRF(FMTHRF(FTHRF(SIVYRVA VITNLA SIVYRVA VITNLA SIVYRVA VITNLA SIVYRVA VITNLA SIVYRVA YARPKAI YVRSFTS YVRSGK YFFPSSI YLKPSS XVRS XVRPSS XVRS XVRS XVRS XVRS XVRS XVRS XVRS XV	266 267 268 267 266 266 266 266 266 266 267 266 267 266 267 266 267 266 267 267 267 269 269 266 266 266 266 266 267 267 267 266 267 266 266 266 266 266 266 266 266 266 266 265 265 265 265 266 265 266 265 268 264	C b, d c, a, b c c c, r, e c, b c, a, b c, a, b c, a, b c, a, b d d e, o, h, s, t c, b a h j k, g m, n i, m, n f, e c a q, l, g, v, w u	

MOR42-3, which have a Cvs in position I. Most ORs show polar residues at position IX and at least one polar residue in positions II and III. Therefore, some of the residues in positions I-IV and IX might serve as polar/charged anchors for the carboxylate group present in the odorants. By contrast, positions V-VIII are mostly occupied by apolar residues, except for MOR42-1 and MOR42-3, in which polar residues are mostly present. As a result, positions V-VIII might form a hydrophobic pocket to accommodate the aliphatic tail of the ligands, except for MOR42-1 and MOR42-3, in which the polar pocket might bind the additional carboxylate group present in dicarboxylic acids. In MOR13-6, which also binds to dicarboxylic acids, the only polar residue that may bind the second carboxylate group is the Ser residue in position V_{2} in addition to positions I and II. Nevertheless, at present, it is difficult to state whether this Ser residue is involved in the binding.

Class #2 ORs

Ligands binding to Class #2 ORs exhibit a very large structural diversity. In the experimentally tested receptors, positions *I*, *II* and *IX* are occupied mostly by apolar groups, positions *IV* and *VII* by polar groups, whilst the chemical nature of positions *III*, *V*, *VI* and *VIII* is similar to that of Class #1 ORs. However, as expected from the great variability of Class #2 ligands, no significant common features could be identified for these positions.

Models built on rhodopsin's structure

By constructing 3D-models of ORs, we could identify 14 other positions (hereafter 1-14 for the sake of clarity) located on helices TM3, TM4, TM5 and TM6, which face the active-site cavity and, therefore, may play an important role in binding the odorants (Fig. 1). In this paper we analyze the possible role of all the residues we identified as putative constituents of the binding pocket and the ligand specificity for some ORs (Table 1 and Fig. 2). The main residues forming the binding pocket are summarized in Table 1. Residues that may form H-bond with ligands are in italics. As our analysis is based on static models, at present it is not possible to identify if some additional residues exist that are not located in the cavity but still might participate to the binding in a dynamic manner.

Most of the Class #1 ORs that bind to *n*-aliphatic carboxylic acids have a His residue in position 3, except for MOR40-1 (Asn), MOR42-1 and MOR42-3 (Tyr), (Fig. 2). Some of these ORs also bind to *n*-aliphatic alcohols. His in position 3 could form an H-bond with the polar group of the ligands. As can be seen from Fig. 1, usually there is a second polar residue present (positions 4, 5 and 9) that can form a second H-bond with the carboxylate group of

carboxylic acids. The aliphatic tail of these ligands might be surrounded by apolar residues in positions *10*, *II* and *III* at TM5 and *12*, *VI*, *VII*, *VIII*, *13* and *IX* at TM6.

The main difficulties in predicting which residues are responsible for binding carboxylic acids and/or alcohols are expected for Class #2 ORs: MOR106-1, MOR106-13P MOR203-1 and MOR204-32. They show sequence diversity and therefore, as can be seen from Table 1, the distribution of polar and/or charged residues in the binding sites is very different within the class and with respect to Class #1 ORs. As a result, it is not possible to formulate a unique model of the binding pocket. For MOR106-1 and MOR203-1, which bind carboxylic acids, we can propose two different binding models. As for MOR106-1, the ligand carboxylate group can bind either Thr in positions 5 or VII. In the MOR203-1 case, one possibility is that Thr in position VII and Tyr in position 13 bind the odorant carboxylate group; the other is that the ligand is coordinated by Thr in position 5 and Asn in position III.

MOR106-13P and MOR204-32 bind alcohols. The first could bind the ligand hydroxyl group with Ser either in position 5 or *VII*. The second could bind the ligand either with Thr in position 5 or *VII*, or with Ser in position *I*.

MOR42-1 and MOR42-3, which bind aliphatic dicarboxylic acids, exhibit polar residues in positions 3 at TM3, and in positions 11, VII, 13, IX at TM6. MOR42-3 also shows a polar residue in position 9 at TM5. Thereby, we may assume that there are two available sites for the binding of the two carboxylate groups. MOR13-6, which also binds aliphatic dicarboxylic acids, exhibits polar residues in positions 5 at TM3 and 13 at TM6. These also could be two sites for binding the two carboxylate groups.

Some ORs that bind aliphatic or aromatic aldehydes, such as MOR103-15, MOR31-6 and MOR171-2 (Table 1 and Fig. 2), exhibit a polar residue at position *VIII*, which contains mostly apolar residues for other ORs. These residues could form H-bonds with the carbonyl group of the ligands. Two other ORs that bind aldehydes, MOR175-1 and MOR258-5, do not have polar residues in position *VIII*. However MOR175-1, which also binds ketones, exhibits polar groups in positions *3* and *VII*, which can form H-bonds. MOR258-5 shows a Ser in position *I*. As MOR258-5 binds ligands that may form several H-bonds, Ser in position *I* is, at present, the only candidate in the putative binding site likely to be involved in H-bond formation with ligands.

Comparison with other models

Our proposal that position 3 forms H-bonds to ligands in most of the ORs that bind carboxylic acids and in MOR175-1 is consistent with previous models [31]. Also our hypothesis that Thr in position *VII* of MOR204-32

forms a H-bond with its ligands (heptanol and hexanol) is consistent with Floriano et al.'s observations [31].

Man et al. proposed a set of 22 amino-acid positions that are important for the ligand binding site [35]. Sixteen of them are located in helices TM3, TM4, TM5 and TM6 [35]. Ten of these positions, located mostly in helices TM3 and TM4 (1, 2, 3, 4, 5, I, 7, 8, III, VIII) are also proposed to be involved in ligand binding in this

work, where the main discrepancies pertain to helices TM5 and TM6.

TM4 is predicted to be part of the stable core of the Class A of GPCRs [45, 46]. This helix has a position conserved in most proteins of Class A and contains Trp (Trp or Tyr in many ORs), which H-bonds to a conserved Asn on TM2. In addition, we have shown that in all Class #1 ORs there is a position in TM4 that is always occupied by a basic residue when that position *IV* in TM5 presents an





c)

Fig. 3 Schematic representations of the interactions between several ORs, for which mutagenesis experiments have been predicted, and their ligands. \mathbf{a} - \mathbf{c} Examples of binding aliphatic carboxylic acids in MOR31-2, MOR31-4 and MOR31-6, respectively. *Half-rounds* in (a) and (c) indicate unfavorable interactions between aliphatic tails of ligands and polar residues in position *VIII*. d and e Right and

wrong orientation of the pentanal bound to the binding site of MOR31-6, respectively. **f** Binding of dicarboxylic acids in MOR42-1 and MOR42-3. A redundant number of possible hydrogen bonds is shown due to several candidate residues suitable for forming H-bond with the second carboxylate group of the ligand

Asp residue. We have therefore assumed that this information is sufficient to include TM4 helix in our model for all Class #1 ORs.

Finally, the ab initio model of MOR103-15 has pointed out that Lys164, located in TM4 (position 8), is the crucial residue for binding aldehydes [32]. This model is supported by free-energy calculations, which proved to be in agreement with experiment. However, our modeling suggests that this residue is disposed in the neighbor of the binding pocket, probably forming a salt bridge with Asp285, whereas Ser in TM6 (position VIII) is the best candidate for binding the carbonyl group of aldehydes: firstly, most ORs that bind aldehydes have a polar or a Cys residue in position VIII in TM6; secondly, it has been shown that in MOR174-9, the most crucial residue for binding the carbonyl group is Ser in TM3 (position 3), [33] despite this OR binding an aldehyde-heptanal-and also having the basic residue His in TM4. MOR171-2 has a Glu residue in position 8 and binds ligands acetophenone and benzaldehyde, which cannot be donors of H-bonds. Finally, MOR276-1 has the polar residue Gln in this position, but it binds an absolutely apolar ligand-limonene. Consequently, this issue could be resolved by including molecular biology data.

Concluding remarks

Our calculations suggest that: (1) residues in positions *I*–*IV*, *IX* and *V*–*VIII* might form electrostatic and van der Waals interactions for most ligands of Class #1 ORs; (2) in Class #2 OR, positions *I*, *II* and *IX* are occupied mostly by apolar groups, positions *IV* and *VII* by polar groups, and the nature of residues at positions *III*, *V*, *VI* and *VIII* is similar to that of Class #1 ORs; (3) other 14 positions (indicated as I-I4 for clarity purposes), in addition to *I*–*IX*, may play an important role for ligand binding.

It is clear that the possibility of performing further mutagenesis experiments could dramatically improve the general comprehension of the odorant recognition process and eventually provide a straightforward validation to our models. We have here emphasized the achievement of Saito et al., [8] who have been able to express a set of 11 ORs by using identified accessory proteins. Therefore, it should now be experimentally possible to test the effect of sitedirected mutagenesis experiments on ligand specificity for this set of ORs.

As for those Ors that bind carboxylic acids (MOR23-1, MOR31-2, MOR31-4, MOR31-6, MOR32-5, MOR32-11 and MOR203-1), [8] the critical experiment is the substitution of the polar groups, which constitute the binding site, with apolar residues (see Table 1). Apart from MOR203-1,

which shows many polar residues facing the binding pocket and possibly participating to the carboxylic acid binding, in order to observe a change in ligand binding affinity, His in position 3 seems the best candidate for mutation (Fig. 3). Since all ORs that bind carboxylic acids show two very close polar residues in positions 3 and 9 (MOR31-2, MOR31-4 and MOR31-6), 3 and 4 (MOR23-1), 3 and II (MOR32-5, MOR32-11), 5 and III or VII and 13 (MOR203-1) (Fig. 2), a double mutation could be necessary to observe a complete loss of affinity for carboxylic acids.

Some mutations could be suggested to modify the affinity for odorants belonging to the same chemical class. For example, MOR31-4 binds n-aliphatic carboxylic acids with a chain length ranging from six to ten carbon atoms, contrary to MOR31-6, which can bind only pentanoic acid (and pentanal) (Fig. 3 and Table 1) [8]. We believe that the main reason for their different behavior is given by the nature of the amino-acid residues in position VIII (a Ser for MOR31-6 and a Gly for MOR31-4). Therefore, in principle MOR31-4 mutation of Gly257 to Ser or bulky residues should reduce OR affinity for long-chain carboxylic acids. However, the very low accuracy of our models does not allow us to establish this point firmly. On the contrary, the mutation of Ser256 in MOR31-6 into Gly should allow the OR to bind longer carboxylic acids. In addition, the mutation of Ser256 into Gly or apolar residues should reduce the affinity of MOR31-6 for pentanal, validating the hypothesis that position VIII is involved in the binding of aldehvdes.

In the case of MOR42-1 and MOR42-3, which bind dicarboxylic acids, we proposed the presence in the binding pocket of two polar regions, constituted by several residues (Fig. 3 and Table 1). We can advance that mutations of the polar residues present in one of these two regions with apolar residues should alter ORs affinity for dicarboxylic acids, whereas the possibility of binding at least one carboxylate group should be conserved.

Acknowledgements We would like to thank Kazushige Touhara and Sayako Katada (University of Tokyo, Japan) for supplying the sequence alignment of bovine rhodopsin and MOR174-9 and the 3D-model structure of the latter, Dr. Alejandro Giorgetti (Università di Roma "La Sapienza", Italy) for useful discussions and Manuela Schipizza Lough (SISSA/ISAS) for reading the text. This work was supported by INFM-Democritos.

References

- 1. Menini A, Lagostena L, Boccaccio A (2004) News Physiol Sci 19:101–104
- 2. Buck L, Axel R (1991) Cell 65:175–187
- 3. Mombaerts P (2004) Nat Rev Neurosci 5:263-278
- Godfrey PA, Malnic B, Buck LB (2004) Proc Natl Acad Sci USA 101:2156–2161
- 5. Malnic B, Hirono J, Sato T, Buck LB (1999) Cell 96:713-723

- Freitag J, Beck A, Ludwig G, von Buchholtz L, Breer H (1999) Gene 226:165–174
- 7. Zhang X, Firestein S (2002) Nat Neurosci 5:124-133
- Saito H, Kubota M, Roberts RW, Chi Q, Matsunami H (2004) Cell 119:679–691
- 9. Araneda RC, Kini AD, Firestein S (2000) Nat Neurosci 3:1248-1255
- Bozza T, Feinstein P, Zheng C, Mombaerts P (2002) J Neurosci 22:3033–3043
- Gaillard I, Rouquier S, Pin JP, Mollard P, Richard S, Barnabe C, Demaille J, Giorgi D (2002) Eur J Neurosci 15:409–418
- Kajiya K, Inaki K, Tanaka M, Haga T, Kataoka H, Touhara K (2001) J Neurosci 21:6018–6025
- Katada S, Nakagawa T, Kataoka H, Touhara K (2003) Biochem Biophys Res Commun 305:964–969
- Katada S, Hirokawa T, Oka Y, Suwa M, Touhara K (2005) J Neurosci 25:1806–1815
- 15. Krautwurst D, Yau KW, Reed RR (1998) Cell 95:917–926
- Levasseur G, Persuy MA, Grebert D, Remy JJ, Salesse R, Pajot-Augy E (2003) Eur J Biochem 270:2905–2912
- 17. Oka Y, Omura M, Kataoka H, Touhara K (2004) EMBO J 23:120–126
- Touhara K, Sengoku S, Inaki K, Tsuboi A, Hirono J, Sato T, Sakano H, Haga T (1999) Proc Natl Acad Sci USA 96:4040–4045
- Zhao H, Ivic L, Otaki JM, Hashimoto M, Mikoshiba K, Firestein S (1998) Science 279:237–242
- 20. Kolakowski LF Jr (1994) Receptors Channels 2:1-7
- Floriano WB, Vaidehi N, Goddard WA III, Singer MS, Shepherd GM (2000) Proc Natl Acad Sci USA 97:10712–10716
- 22. Pebay-Peyroula E, Rummel G, Rosenbusch JP, Landau EM (1997) Science 277:1676–1681
- 23. Singer MS, Shepherd GM (1994) Neuroreport 5:1297-1300
- 24. Singer MS, Oliveira L, Vriend G, Shepherd GM (1995) Receptors Channels 3:89–95
- 25. Afshar M, Hubbard RE, Demaille J (1998) Biochimie 80:129-135
- 26. Schertler GF, Villa C, Henderson R (1993) Nature 362:770-772
- 27. Schertler GF (1998) Eye 12 (Pt 3b):504-510

- 28. Singer MS (2000) Chem Senses 25:155-165
- Vaidehi N, Floriano WB, Trabanino R, Hall SE, Freddolino P, Choi EJ, Zamanakos G, Goddard WA III (2002) Proc Natl Acad Sci USA 99:12622–12627
- 30. Lai PC, Singer MS, Crasto CJ (2005) Chem Senses 30:781-792
- Floriano WB, Vaidehi N, Goddard WA III (2004) Chem Senses 29:269–290
- Hall SE, Floriano WB, Vaidehi N, Goddard WA III (2004) Chem Senses 29:595–616
- Hummel P, Vaidehi N, Floriano WB, Hall SE, Goddard WA III (2005) Protein Sci 14:703–710
- Trabanino RJ, Hall SE, Vaidehi N, Floriano WB, Kam VW, Goddard WA III (2004) Biophys J 86:1904–1921
- 35. Man O, Gilad Y, Lancet D (2004) Protein Sci 13:240-254
- Palczewski K, Kumasaka T, Hori T, Behnke CA, Motoshima H, Fox BA, Le Trong I, Teller DC, Okada T, Stenkamp RE, Yamamoto M, Miyano M (2000) Science 289:739–745
- 37. Khalid S, Bond PJ, Deol SS, Sansom MS (2006) Proteins 63:6
- Oakhill JS, Sutton BJ, Gorringe AR, Evans RW (2005) Protein Eng Des Sel 18:221–228
- Zhang Y, Sham YY, Rajamani R, Gao J, Portoghese PS (2005) Chembiochem 6:853–859
- Eilers M, Hornak V, Smith SO, Konopka JB (2005) Biochemistry 44:8959–8975
- Thompson JD, Higgins DG, Gibson TJ (1994) Nucleic Acids Res 22:4673–4680
- 42. Sali A, Blundell TL (1993) J Mol Biol 234:779-815
- Okada T, Sugihara M, Bondar AN, Elstner M, Entel P, Buss V (2004) J Mol Biol 342:571–583
- 44. Cornell WD, Cieplak P, Bayly CI, Gould IR, Caldwell JW, Kollman PA (1995) J Am Chem Soc 117:5179–5197
- Lin JC, Parrish W, Eilers M, Smith SO, Konopka JB (2003) Biochemistry 42:293–301
- Liu W, Eilers M, Patel AB, Smith SO (2004) J Mol Biol 337:713– 729
- 47. Humphrey W, Dalke A, Schulten K (1996) J Mol Graph 14:33-38